Table of Contents
- 2 Erin Griffith
- 4 Erin Griffith
- 6 Erin Griffith
- 8 Erin Griffith
- 10 Erin Griffith
- 12 Erin Griffith
- 14 Erin Griffith
- 16 Erin Griffith
- 18 Erin Griffith
- 20 Erin Griffith
- 22 Erin Griffith
- 24 Erin Griffith
- 26 Erin Griffith
- 28 Erin Griffith
- 30 Erin Griffith
- 32 Erin Griffith
- 34 Erin Griffith
- 36 Erin Griffith
- 38 Erin Griffith
- 40 Erin Griffith
- 42 Erin Griffith
- 44 Erin Griffith
- 46 Erin Griffith
- 48 Erin Griffith
- 50 Erin Griffith
- 52 Erin Griffith
- 54 Erin Griffith
- 56 Erin Griffith
- 58 Erin Griffith
- 60 Erin Griffith
- 62 Erin Griffith
- 64 Erin Griffith
- 66 Erin Griffith
- 68 Erin Griffith
- 70 Erin Griffith
- 72 Erin Griffith
- 74 Erin Griffith
- 76 Erin Griffith
- 78 Erin Griffith
- 80 Erin Griffith
- 82 Erin Griffith
- 84 Erin Griffith
- 86 Erin Griffith
- 88 Erin Griffith
- 90 Erin Griffith
- 92 Erin Griffith
- 94 Erin Griffith
- 96 Erin Griffith
- 98 Erin Griffith
- 100 Erin Griffith
- 102 Erin Griffith
- 104 Erin Griffith
- 106 Erin Griffith
- 108 Erin Griffith
- 110 Erin Griffith
- 112 Erin Griffith
- 114 Erin Griffith
- 116 Erin Griffith
- 118 Erin Griffith
- 120 Erin Griffith
- 122 Erin Griffith
- 124 Erin Griffith
- 126 Erin Griffith
- 128 Erin Griffith
- 130 Erin Griffith
- 132 Erin Griffith
- 134 Erin Griffith
- 136 Erin Griffith
- 138 Erin Griffith
- 140 Erin Griffith
- 142 Erin Griffith
- 144 Erin Griffith
- 146 Erin Griffith
- 148 Erin Griffith
- 150 Erin Griffith
- 152 Erin Griffith
- 154 Erin Griffith
- 156 Erin Griffith
- 158 Erin Griffith
- 160 Erin Griffith
- 162 Erin Griffith
- 164 Erin Griffith
- 166 Erin Griffith
- 168 Erin Griffith
- 170 Erin Griffith
- 172 Erin Griffith
- 174 Erin Griffith
- 176 Erin Griffith
- 178 Erin Griffith
- 180 Erin Griffith
- 182 Erin Griffith
- 184 Erin Woo
- 186 Erin Woo
- 188 Erin Woo
- 190 Erin Woo
- 192 Erin Woo
- 194 Erin Woo
- 196 Erin Woo
- 198 Erin Woo
- 200 Erin Woo
- 202 Erin Woo
- 204 Erin Woo
- 206 Erin Woo
- 208 Erin Woo
- 210 Erin Woo
- 212 Erin Woo
- 214 Erin Woo
- 216 Erin Woo
- 218 Erin Woo
- 220 Erin Woo
- 222 Erin Woo
- 224 Erin Woo
- 226 Erin Woo
- 228 Erin Woo
- 230 Erin Woo
- 232 Erin Woo
- 234 Erin Griffith
- 236 Erin Griffith
- 238 Erin Griffith
- 240 Erin Griffith
- 242 Erin Griffith
- 244 Erin Griffith
- 246 Erin Griffith
- 248 Erin Griffith
- 250 Erin Griffith
- 252 Erin Griffith
- 254 Erin Griffith
- 256 Erin Griffith
- 258 Erin Griffith
- 260 Erin Griffith
- 262 Erin Griffith
- 264 Erin Griffith
- 266 Erin Griffith
- 268 Erin Griffith
- 270 Erin Griffith
- 272 Erin Griffith
- 274 Erin Griffith
- 276 Erin Griffith
- 278 Erin Griffith
- 280 Erin Griffith
- 282 Erin Griffith
- 284 Erin Griffith
- 286 Erin Griffith
- 288 Erin Griffith
- 290 Erin Griffith
- 292 Erin Griffith
- 294 Erin Griffith
- 296 Erin Griffith
- 298 Erin Griffith
- 300 Erin Griffith
- 302 Erin Griffith
- 304 Erin Griffith
- 306 Erin Griffith
- 308 Erin Griffith
- 310 Erin Griffith
- 312 Erin Griffith
- 314 Erin Griffith
- 316 Erin Griffith
- 318 Erin Griffith
- 320 Erin Griffith
- 322 Erin Griffith
- 324 Erin Griffith
- 326 Erin Griffith
- 328 Erin Griffith
- 330 Erin Griffith
- 332 Erin Griffith
- 334 Erin Griffith
- 336 Erin Griffith
- 338 Erin Griffith
- 340 Erin Griffith
- 342 Erin Griffith
- 344 Erin Griffith
- 346 Erin Griffith
- 348 Erin Griffith
- 350 Erin Griffith
- 352 Erin Griffith
- 354 Erin Griffith
- 356 Erin Griffith
- 358 Erin Griffith
- 360 Erin Griffith
- 362 Erin Griffith
- 364 Erin Griffith
- 366 Erin Griffith
- 368 Erin Griffith
- 370 Erin Griffith
- 372 Erin Griffith
- 374 Erin Griffith
- 376 Erin Griffith
- 378 Erin Griffith
- 380 Erin Griffith
- 382 Erin Griffith
- 384 Erin Griffith
- 386 Erin Griffith
- 388 Erin Griffith
- 390 Erin Griffith
- 392 Erin Griffith
- 394 Erin Griffith
- 396 Erin Griffith
- 398 Erin Griffith
- 400 Erin Griffith
- 402 Erin Griffith
- 404 Erin Griffith
- 406 Erin Griffith
- 408 Erin Griffith
- 410 Erin Griffith
- 412 Erin Griffith
- 414 Erin Griffith
- 416 Erin Griffith
- 418 Erin Griffith
- 420 Erin Griffith
- 422 Erin Griffith
- 424 Erin Griffith
- 426 Erin Griffith
- 428 Erin Griffith
- 430 Erin Griffith
- 432 Erin Griffith
- 434 Erin Griffith
- 436 Erin Griffith
- 438 Erin Griffith
- 440 Erin Griffith
- 442 Erin Griffith
- 444 Erin Griffith
- 446 Erin Woo
- 448 Erin Woo
- 450 Erin Woo
- 452 Erin Woo
- 454 Erin Woo
- 456 Erin Woo
- 458 Erin Woo
- 460 Erin Woo
- 462 Erin Woo
- 464 Erin Woo
- 466 Erin Woo
- 468 Erin Woo
- 470 Erin Woo
- 472 Erin Woo
- 474 Erin Woo
- 476 Erin Woo
- 478 Erin Woo
- 480 Erin Woo
- 482 Erin Woo
- 484 Erin Woo
- 486 Erin Woo
- 488 Erin Woo
- 490 Erin Woo
- 492 Erin Woo
- 494 Erin Woo
- 496 Erin Woo
- 498 Erin Woo
- 500 Erin Woo
- 502 Erin Woo
- 504 Erin Woo
- 506 Erin Woo
- 508 Erin Woo
- 510 Erin Woo
- 512 Erin Woo
- 514 Erin Woo
- 516 Erin Woo
- 518 Erin Woo
- 520 Erin Woo
- 522 Erin Woo
- 524 Erin Woo
- 526 Erin Woo
- 528 Erin Woo
- 530 Erin Woo
- 532 Erin Woo
- 534 Erin Woo
- 536 Erin Woo
- 538 Erin Woo
- 540 Erin Woo
- 542 Erin Woo
- 544 Erin Woo
- 546 Erin Woo
- 548 Erin Woo
- 550 Erin Woo
- 552 Erin Woo
- 554 Erin Woo
- 556 Erin Woo
- 558 Erin Woo
- 560 Erin Woo
- 562 Erin Woo
- 564 Erin Griffith
- 566 Erin Woo
- 568 Erin Griffith
- 570 Erin Woo
- 572 Erin Woo
- 574 Erin Woo
- 576 Erin Woo
- 578 Erin Griffith
- 580 Erin Griffith
- 582 Erin Griffith
- 584 Erin Woo
- 586 Erin Woo
- 588 Erin Griffith
- 590 Erin Griffith
- 592 Erin Griffith
- 594 Erin Woo
- 596 Erin Woo
- 598 Erin Griffith
- 600 Erin Griffith
- 602 Erin Woo
- 604 Erin Griffith
- 606 Erin Griffith
- 608 Erin Griffith
- 610 Erin Griffith
- 612 Erin Griffith
- 614 Erin Woo
- 616 Erin Woo
- 618 Erin Woo
- 620 Erin Woo
- 622 Erin Woo
- 624 Erin Woo
- 626 Erin Woo
- 628 Erin Woo
- 630 Erin Woo
- 632 Erin Woo
- 634 Erin Woo
- 636 Erin Woo
- 638 Erin Woo
- 640 Erin Woo
- 642 Erin Woo
- 644 Erin Woo
- 646 Erin Woo
- 648 Erin Woo
- 650 Erin Woo
- 652 Erin Woo
- 654 Erin Woo
- 656 Erin Woo
- 658 Erin Woo
- 660 Erin Woo
- 662 Erin Woo
- 664 Erin Woo
- 666 Erin Woo
- 668 Erin Woo
- 670 Erin Woo
- 672 Erin Griffith
- 674 Erin Griffith
- 676 Erin Griffith
- 678 Erin Griffith
- 680 Erin Griffith
- 682 Erin Griffith
- 684 Erin Griffith
- 686 Erin Griffith
- 688 Erin Griffith
- 690 Erin Griffith
- 692 Erin Griffith
- 694 Erin Griffith
- 696 Erin Griffith
- 698 Erin Griffith
- 700 Erin Griffith
- 702 Erin Griffith
- 704 Erin Griffith
- 706 Erin Griffith
- 708 Erin Griffith
- 710 Erin Griffith
- 712 Erin Griffith
- 714 Erin Griffith
- 716 Erin Griffith
- 718 Erin Griffith
- 720 Erin Griffith
- 722 Erin Griffith
- 724 Erin Griffith
- 726 Erin Griffith
- 728 Erin Griffith
- 730 Erin Griffith
- 732 Erin Griffith
- 734 Erin Griffith
- 736 Erin Griffith
- 738 Erin Griffith
- 740 Erin Griffith
- 742 Erin Griffith
- 744 Erin Griffith
- 746 Erin Griffith
- 748 Erin Griffith
- 750 Erin Griffith
- 752 Erin Griffith
- 754 Erin Griffith
- 756 Erin Griffith
- 758 Erin Griffith
- 760 Erin Griffith
- 762 Erin Griffith
- 764 Erin Griffith
- 766 Erin Griffith
- 768 Erin Griffith
- 770 Erin Griffith
- 772 Erin Griffith
- 774 Erin Griffith
- 776 Erin Griffith
- 778 Erin Griffith
- 780 Erin Griffith
- 782 Erin Griffith
- 784 Erin Griffith
- 786 Erin Griffith
- 788 Erin Griffith
- 790 Erin Griffith
- 792 Erin Griffith
- 794 Erin Griffith
- 796 Erin Griffith
- 798 Erin Woo
- 800 Erin Woo
- 802 Erin Woo
- 804 Erin Woo
- 806 Erin Woo
- 808 Erin Woo
- 810 Erin Woo
- 812 Erin Woo
- 814 Erin Woo
- 816 Erin Woo
- 818 Erin Woo
- 820 Erin Woo
- 822 Erin Woo
- 824 Erin Woo
- 826 Erin Woo
- 828 Erin Woo
- 830 Erin Woo
- 832 Erin Woo
- 834 Erin Woo
- 836 Erin Woo
- 838 Erin Woo
- 840 Erin Woo
- 842 Erin Woo
- 844 Erin Woo
- 846 Erin Woo
- 848 Erin Woo
- 850 Erin Woo
- 852 Erin Woo
- 854 Erin Woo
- 856 Erin Woo
- 858 Erin Woo
- 860 Erin Woo
- 862 Erin Woo
- 864 Erin Woo
- 866 Erin Woo
- 868 Erin Woo
- 870 Erin Woo
- 872 Erin Woo
- 874 Erin Woo
- 876 Erin Woo
- 878 Erin Woo
- 880 Erin Woo
- 882 Erin Woo
- 884 Erin Woo
- 886 Erin Woo
- 888 Erin Woo
- 890 Erin Woo
- 892 Erin Woo
- 894 Erin Woo
- 896 Erin Woo
- 898 Erin Woo
- 900 Erin Woo
- 902 Erin Woo
- 904 Erin Woo
- 906 Erin Woo
- 908 Erin Woo
- 910 Erin Woo
- 912 Erin Woo
- 914 Erin Woo
- 916 Erin Woo
- 918 Erin Woo
- 920 Erin Woo
- 922 Erin Woo
- 924 Erin Woo
- 926 Erin Woo
- 928 Erin Woo
- 930 Erin Woo
- 932 Erin Woo
- 934 Erin Woo
- 936 Erin Woo
- 938 Erin Woo
- 940 Erin Woo
- 942 Erin Woo
- 944 Erin Woo
- 946 Erin Woo
- 948 Erin Woo
- 950 Erin Woo
- 952 Erin Woo
- 954 Erin Woo
- 956 Erin Woo
- 958 Erin Woo
- 960 Erin Woo
- 962 Erin Woo
- 964 Erin Woo
- 966 Erin Woo
- 968 Erin Woo
- 970 Erin Woo
- 972 Erin Woo
- 974 Erin Woo
- 976 Erin Woo
- 978 Erin Woo
- 980 Erin Woo
- 982 Erin Woo
- 984 Erin Woo
- 986 Erin Woo
- 988 Erin Woo
- 990 Erin Woo
- 992 Erin Woo
- 994 Erin Woo
- 996 Erin Woo
- 998 Erin Woo
- 1000 Erin Woo
- 1002 Erin Woo
- 1004 Erin Woo
- 1006 Erin Woo
- 1008 Erin Woo
- 1010 Erin Woo
- 1012 Erin Woo
- 1014 Erin Woo
- 1016 Erin Woo
- 1018 Erin Woo
- 1020 Erin Woo
- 1022 Erin Woo
- 1024 Erin Woo
- 1026 Erin Woo
- 1028 Erin Woo
- 1030 Erin Woo
- 1032 Erin Woo
- 1034 Erin Woo
- 1036 Erin Woo
- 1038 Erin Woo
- 1040 Erin Woo
- 1042 Erin Woo
- 1044 Erin Woo
- 1046 Erin Woo
- 1048 Erin Woo
- 1050 Erin Woo
- 1052 Erin Woo
- 1054 Erin Woo
- 1056 Erin Woo
- 1058 Erin Woo
- 1060 Erin Woo
- 1062 Erin Woo
- 1064 Erin Woo
- 1066 Erin Woo
- 1068 Erin Woo
- 1070 Erin Woo
- 1072 Erin Woo
- 1074 Erin Woo
- 1076 Erin Woo
- 1078 Erin Woo
- 1080 Erin Woo
- 1082 Erin Woo
- 1084 Erin Woo
- 1086 Erin Woo
- 1088 Erin Woo
- 1090 Erin Woo
- 1092 Erin Woo
- 1094 Erin Woo
- 1096 Erin Woo
- 1098 Erin Woo
- 1100 Erin Griffith
- 1102 Erin Griffith
- 1104 Erin Griffith
- 1106 Erin Griffith
- 1108 Erin Griffith
- 1110 Erin Griffith
- 1112 Erin Griffith
- 1114 Erin Griffith
- 1116 Erin Griffith
- 1118 Erin Griffith
- 1120 Erin Griffith
- 1122 Erin Griffith
- 1124 Erin Griffith
- 1126 Erin Griffith
- 1128 Erin Griffith
- 1130 Erin Griffith
- 1132 Erin Griffith
- 1134 Erin Griffith
- 1136 Erin Griffith
- 1138 Erin Griffith
- 1140 Erin Griffith
- 1142 Erin Griffith
- 1144 Erin Griffith
- 1146 Erin Griffith
- 1148 Erin Griffith
- 1150 Erin Griffith
- 1152 Erin Griffith
- 1154 Erin Griffith
- 1156 Erin Griffith
- 1158 Erin Griffith
- 1160 Erin Griffith
- 1162 Erin Griffith
- 1164 Erin Griffith
- 1166 Erin Griffith
- 1168 Erin Griffith
- 1170 Erin Griffith
- 1172 Erin Griffith
- 1174 Erin Griffith
- 1176 Erin Griffith
- 1178 Erin Griffith
- 1180 Erin Griffith
- 1182 Erin Griffith
- 1184 Erin Griffith
- 1186 Erin Griffith
- 1188 Erin Griffith
- 1190 Erin Woo
- 1192 Erin Woo
- 1194 Erin Woo
- 1196 Erin Woo
- 1198 Erin Woo
- 1200 Erin Woo
- 1202 Erin Woo
- 1204 Erin Woo
- 1206 Erin Woo
- 1208 Erin Woo
- 1210 Erin Woo
- 1212 Erin Woo
- 1214 Erin Woo
- 1216 Erin Woo
- 1218 Erin Griffith
- 1220 Erin Griffith
- 1222 Erin Griffith
- 1224 Erin Griffith
- 1226 Erin Griffith
- 1228 Erin Griffith
- 1230 Erin Griffith
- 1232 Erin Griffith
Kevin Downey, Holmes’s lawyer, is cross-examining Eisenman. Raising his voice a bit asking about his investment experience and about his conversations with Holmes. Pointing out that Eisenman only had one short call with Holmes before investing.
Eisenman emails again asking for more info about potentially selling his shares. Balwani’s response: “Your emails are insulting full of inaccurate statements and wasteful of our time. Our next response to this email and all your future emails will come from our counsel.”
Guy was told an IPO was coming almost a decade earlier and now can’t get a call back. He is now sending emails with PLEASE RESPOND!!! in the subject lines. And Balwani responds with “I already responded to you”
Eisenman responds asking for more info and Balwani responds with this: Alan. I have no intention of responding to this email and explaining the tech and processes. Please stop sending me with emails everyday. thanks.
Eisenman emails Holmes and Balwani a negative UBS report about Theranos. Balwani responds that it “sounds like an uninformed consultant”
And despite all that, Eisenman STILL invested $99,990 into Theranos in 2013. Why? “This is called a seat at the table.”
Before it was fundraising, Eisenman testifies that Sunny Balwani was “not only nonresponsive but aggressive with me.” “To say minimally, he was hostile for an extended period of time.”
Then Theranos was raising money again and it sounds like *despite all of this drama* Eisenman was willing to invest more money!
He responded: “It has been over 2 years since you have communicated with your investors. … Does this mean that you can’t or won’t communicate with me or the other investors?
From there things got spicy. Eisenman reached out Don Lucas asking for information. Lucas forwarded it to Holmes and she responded: “Alan, we have communicated about this multiple times before yet you choose to continue going down this path. Elizabeth”
In a May 2010 email, Eisenman asks Holmes whether the company hit the $200m revenue it predicted for 2009. In a later email, he testifies, Holmes said that goal was “stretched another year.”
His push for more information about Theranos’s performance frustrated Holmes. “I was more proactive than most. … Management didn’t like the fact that I was trying to communicate and get information.” To solve that problem, Holmes offered to buy him out at a 5x return.
Over time Eisenman asked Holmes to keep her quarterly updates coming and was denied. “There was no information coming from the company. To me that’s a sign of trouble.”
Theranos told investors it would become cash flow positive by the end of ’08. Now we’re going on a break.
In ’09 Theranos was telling Eisenman about huge demand for its cartridges. “These are numbers that are pretty astounding and create a pretty significant value for this company,” he said.
Altogether Eisenman’s family invested just under $1.2m into Theranos. ($900k for him and his wife, $90k for each of three kids) His testimony follows a pattern that is very familiar by now: What he understood about what Theranos’s technology could do and how he learned it.
Eisenman had many one-on-one calls with Holmes and she was the main source of info on the company. In 2006 Holmes was already saying she was talking to bankers about an IPO in the next 12-18 months and claiming $50m-60m in revenue in ’07 and $200m in ’08.
Eisenman testifies that, around 2006, he was told that Larry Ellison was on Theranos’s board and was taking $20 million of an upcoming $30 million fundraise. “My understanding was these international pharma companies had adopted this tech in some of their clinical trails.”
Alan Eisenman, a Theranos investor, is now on the stand. He was introduced to the company by the Holmes family’s financial adviser in Houston.
Das testimony ends with a very awkward exchange where Wade prompted him to recall a quote from the Best Exotic Marigold Hotel. “Everything will be alright in the end and if it’s not alright, it’s not yet the end.” Why was that relevant? I dunno.
Defense has spent time in testimony painting Holmes as an inexperienced person who could never have understood the details of how a lab works. Prosecution pointed out that she was CEO of the company and touted the patents she claimed to have written.
We also heard more about the Holmes excuse for the lab problems — she blamed it on quality control issues, not the machines. Apparently that excuse was given to CMS in a letter that Das signed, even though he disagreed with that part.
Dr. Das was asked in cross-exam about whether his decision to void the tests was “conservative.” In redirect, he was asked about it again and he said, “I was just following the data.”
Back to cross-exam. We see an email in April 2016 from Dr. Das to Holmes titled “some good news, for once” — data from two valuations looked “excellent” he wrote, even though he was not “a fan of the studies themselves.”
Now they’re doing a sidebar about scheduling, which I really wish would be a main bar so the press could have any sense whatsoever of what to expect and plan around…
One issue: Eisenman, who invested in Theranos, apparently said something about punishment of Holmes in the hallway and defense is concerned about that. And secondly, they’re redacting a line from an email that says he had most of his net worth (‼️) tied up in Theranos
During a break the lawyers are fighting over the upcoming testimony of Alan Eisenman.
Wade makes it seem like Theranos was heroic for voiding the tests, given media scrutiny and stakes: It was a big decision to make to void all of the assays for their analyzers? It wasn’t necessarily something anyone wanted to do? The preference would be not to have to do that?
Now Wade attempts to blame former lab director Adam Rosendorff (without mentioning that he resigned in frustration and leaked to WSJ). You recall the laboratory was not well-run when you joined? And that was why you were working to improve it?
Now Wade blames Das: You’re familiar with Holmes’s background and training? She wouldn’t be qualified to serve as a lab director in a high complexity lab? But you were qualified? Ultimately the judgments were yours? You were responsible for the people working under you?
We talk about all the people working on addressing the problems. Wade: “All these people were working hard and in good faith as they were undertaking these efforts, is that fair?” Das says yes (obviously).
Wade is deflecting blame to Sunny Balwani, who was in charge of the lab. Before Dr. Das, lab directors reported to Balwani. When Das joined, he reported directly to Holmes, and Wade elicits testimony that this was a change designed to address the issues.
Before Dr. Das joined Theranos, CMS inspected Theranos’s labs and issued a damning report about lab deficiencies, which we saw yesterday.
🩸 “Our Holmes Matter” continues in San Jose. 🩸Holmes lawyer Lance Wade is questioning Dr. Das, Theranos’s final lab director. Yesterday he testified that he decided to void as many as 60k Theranos tests.
Dr. Das testifies that Theranos voided 50k-60k tests run on Edison machines — all test run on the machines. Patients got “corrected” reports that just said VOID. Prosecution is done with Dr. Das.
Das testifies about something called a “10x warning” on Feb. 25, 2015, when results come in either above or below the proper range 10 times in a row. He says Theranos continued to report patient results after the 10x warning.
Das disagreed — “the validation data had no bearing on the QA program” — and Theranos never resumed testing on those machines. He concludes: “I found these instruments to be unsuitable for clinical use.”
Holmes suggested they give CMS an alternate explanation that the problem was “not an instrument failure but a failure of the quality control / quality assurance program.”
Das testifies that Theranos voided its tests from that 2014-2015 period. He explained to Holmes that “these instruments were malperforming from the very beginning.”
The report goes further, noting “a possible patient impact for every test reported from the lab’s TPSU 3.5 instruments.” “The fraction of patient results truly impacted and the nature and magnitude of any effect are unknown.”
The response includes such phrases as “High rates of 102s QC rule failures” and “DC CVs far exceeding limits for a stable testing process” which Das simplifies by saying: “It means there was a lot of imprecision noted.”
Das testifies that he had to respond to CMS with a patient impact assessment out of a regulatory, professional and ethical obligation.
Das testifies that he explained the issues to Holmes using the example of female patients returning abnormal PSA levels (a prostate test) because “females should generally not have PSA detectable.”
The CMS report shows that in numerous months between 2014 and 2015, a number of types of tests showed that 15 percent of tests were violating a common quality control rule.
There’s a list of “conditions” that were not met, including “analytic systems,” meaning the instruments and methods used. Das testifies that he discussed the issues with Holmes and the Theranos team.
In Nov 2015, CMS did an onsite survey of Theranos’s CLIA lab. In January 2016, CMS sent Theranos a notice with the heading: CONDITION LEVEL DEFICIENCIES – IMMEDIATE JEOPARDY
Dr. Das was working on a CMS audit while at Theranos. We discuss a “statement of deficiencies” that was 121 pages long.
(He joined officially in March 2016, long after Theranos had publicly launched.)
Wow, Das testifies that when he started as lab director, he was not aware that of Theranos performing any tests that it had developed in-house. No tests on Edison, Minilab or TSPU. No tests on finger stick samples.
Defense is chiming in along the way in opposition of this document; the judge shoots it down as it is already in evidence.
Kingshuk Das, a Theranos lab director, has taken the stand. Lowering the lights to show exhibits on a projector in the courtroom feels a bit like a Junior High science class. We see CLIA Lab rules that shows CMS (fed regulators) can revoke CLIA certificates for rule violations.
Redirect and re-cross were extremely short and Sawyer is excused. We’re breaking and another former lab director — Kingshuk Das — is up after lunch. I will be getting a ticket to go to the courtroom so I can actually see the projected exhibits!
That error was discovered when Theranos was preparing for an audit of its Clia lab. Sawyer says she wasn’t sure if it was in prep for one or as a result of one. And with that Wade is done.
Again we discuss that Sawyer agreed to stay at Theranos six weeks after her initial contract. Apparently the paperwork had been processed incorrectly and she was still listed as the lab director for a bit and Daniel Young reached out to her about it.
Wade asks about “an elaborate process where they warmed finger and noted places to draw from.” Sawyer: “That’s pretty standard for finger sticks.”
Talkin’ ’bout QA QC LDTs (quality assurance quality control lab developed tests). Wade asks Sawyer if she signed off on an LDT for finger stick testing. “Had you ever seen such an elaborate and specific procedure?” Sawyer says no.
Lance Wade, a lawyer for Holmes, pushed Sawyer to say she only asked for the list once. We also discuss an email where Sawyer agreed to extend her time at Theranos (meant to undercut her comments that she quit over concerns about the lab).
The defense is continuing its cross-exam of Lynette Sawyer, who was a co-director of the Theranos lab for six months. Sawyer had testified that she was frustrated that Theranos did not give her a list of the lab employees.
They’re projecting the exhibits onto a wall, which is not really coming through in the overflow room. A juror had to run and get glasses. The judge says he’s “very embarrassed” that the courtroom is having these problems and apologizes.
Fun times, we still have not started because of some kind of technical problem.
Back in San Jose for another day of testimony in U.S. v. Holmes. The lawyers are once again fighting about upcoming testimony.
She resigned in 2015 because she was “very uncomfortable about the lack of clarity about the lab” and who was in it. There was not even a person she could reach out to to talk about issues she had with the documents she was meant to sign off on.
She never got reports about lab activities. She only saw documents about F.D.A.-approved tests on regular blood analyzers. She had no understanding that Theranos was using its own devices on assays. Whew.
She never met Elizabeth Holmes. She never met her lab co-director (the longtime dermatologist of Sunny Balwani). Her job was to sign Docusign documents that she had no ability to edit.
So, Dr. Sawyer became co-director of the lab after Rosendorff left. She was told nothing about his departure. She never went to Theranos’s lab. Never knew anything about it developing its own tests. Never heard of Edison, Minilab, or any of Theranos’s labs.
New witness for the last 30 minutes of the day. The U.S. has called Lynette Sawyer. She was a co-director of Theranos’s California clinical lab between 2014 and 2015. She was originally meant to be a fill-in for 2-3 months.
During that time, was Ms. Holmes still your primary source of information about Theranos? Lucas says yes. Lucas also testifies he didn’t have any information about Theranos’s financial situation before investing in 2013.
Defense made some points earlier about Holmes’s age. Lucas incorrectly estimated her age as 19 when he first invested (she was 21). In re-cross, Bostic points out that she was 29 with a decade at the helm of Theranos by the time Lucas’s second investment was made.
Defense points out that Lucas got a 2.5 percent fee and 16 percent of the upside for investments he made on behalf of Hall Group into Theranos. Black Diamond Ventures got similar terms on the investments made into Theranos on behalf of 30 individuals.
Downey tried to make the point that Lucas’s rush to get into the late 2013 deal may have been to get in at a lower price since Theranos was also planning another round of funding at a higher price the next year.
For the last 30 minutes or so we have done a deep dive into the minutia of Black Diamond’s 2006 investment. Which funds, the closes, the co-investors, the price, the dollar amounts.
Once again we are shown a million-dollar investment amount with a 25 cents on the end. Downey asks Lucas to explain that and he offers up a, “Really? You want me to answer that?” (The reason is to make it an even number of shares.)
We’re going on a break and counsel plans to talk about “that morning matter” which was a cryptic thing about “transactions” before we return. No idea what it could be.
Downey spends a lot of time on Theranos’s patents and I’m not sure what the upshot is besides showing that having a patent is a positive for investors. Lucas says developing the technology is more important.
Downey shows Lucas a list of standard due diligence documents — corporate records, and IP lists, and material agreements, etc. Did Lucas look at these for Theranos? “No we did not conduct all of this.”
Downey asks if its customary for VC firms to retain a law firm for diligence in deals and whether Don Lucas or Pete Thomas of ATA Ventures, another Theranos V.C. investor, did so. Chris Lucas says he doesn’t know.
Lucas is now being cross-examined by Kevin Downey. Did he engage in the normal process of assessing a company? “I don’t remember how much diligence we did. This was a situation where Don had already been on the board. … Obviously we felt very comfortable.”
Once again, we see the Parloff Fortune article. At issue is not the fact that the article had inaccurate info (which Fortune later corrected), it’s that Holmes sent it to so many investors. “Great article!” Lucas says. “Very proud of the situation, proud we were involved, very proud of Elizabeth, the whole thing.”
Why didn’t Holmes want to give full financials to investors? Trade secrets. “She was very concerned, and potentially rightly so, that what she was working on was very transformative and they did not want to have any information get out into the public domain so as to give one of her competitors a chance to crush the company before the company got to fruition.”
Lucas testifies that the risk profile of his two investments in Theranos were very different: In 2006, it was early stage and high risk. By the latest stage 2013 deal, “the risk goes down and you would hope to have a higher certainty of return.”
Lucas testifies that it was very unusual to invest without getting full financials from a portfolio company but he felt comfortable doing it with Theranos because of his relationship with Holmes.
U.S. Attorney John Bostic goes through all the legalese in the investment docs, since we know that the defense will try to use these disclaimers that say investors acknowledge risk and are sophisticated etc. in its cross-exam.
This is a wire fraud case so we gotta talk about the actual, you know, money wires. Lucas discusses the logistics of the wire transfer from Lucas’s fund to Theranos, which, fun fact, is actually officially named Real-Time Cures.
Why the urgency? Because Walgreens had to convert its $40 million note to equity by the end of the year. Lucas says he supported that because “You want more people in the wagon helping fund the company.”
Lucas was also wary of how quickly Theranos was trying to close the round. Two weeks between opening the round and closing was “quite compressed.”
We see a list of questions that Lucas emailed to Holmes in advance of the 2013 investment. He was pushing her on when investors could get a liquidity event.
~ Checking the boxes ~ Prosecutor John Bostic asks about all the various (inaccurate) claims Theranos made about its technology, partnerships, expansion plans, accuracy, etc. Was that an important factor in investing and why? Every investor has gotten this list of questions.
In 2013, the firm invested $5.4 million. Holmes was his main source of info for Theranos. His uncle secondary. They frequently had meals together and knew each other socially. But “there was not a lot of transparency” about what was going on in the company, he said.
In 2006, Black Diamond Ventures invested $1.5 million into Theranos. “It was certainly beyond a drawing on a napkin but we didn’t believe at that time that is was functional and fully developed.”
Chris Lucas founded the firm in 1998. Don Lucas introduced him to Holmes, who he said this about: “She’s very passionate about the project. Very sincere in what she was trying to do. Worked all the time. It was all Theranos all the time for Elizabeth.”
🩸🩸Back in court today for U.S. v. Holmes.🩸🩸 The United States has called Christopher Lucas, whose firm Black Diamond Ventures was an early investor Theranos. He is the nephew of the famed investor Donald Lucas.
After a very efficient redirect, Mosley is done, and court is ending for the day. Trial will resume at 9:30 a.m. Pacific time tomorrow.
Did Theranos currently have revenue? Yes. Use its own devices? Yes. Schenk: “Did you think Ms. Holmes had a vision that one day Pfizer would write something good about Theranos?” No, he read it as a study that had already occurred.
All of Schenk’s questions are about whether Mosley thought Theranos’s claims were current, or Ms. Holmes’s vision. Over and over, Mosley’s saying that he thought Theranos was currently doing these things.
Mosley said he had an understanding that Theranos could perform accurate tests. Again, that came from the materials. He also thought they had a healthy relationship with Walgreens at the time, from the materials and the Fortune article.
Schenk: Did you understand that Theranos could currently perform a vast array of tests? Mosley: I did. Mosley testifies that understanding came from the written materials.
Cross is done, and we’re onto redirect. Schenk says he has just “a couple of questions.”
Back to some of the website language that came up in Edlin’s testimony. “Occasionally, a venipuncture may be required based on the lab order, but this is uncommon, and our aim is to eliminate this entirely.” Mosley: “I don’t believe I knew this at the time.
We’re looking at an archived copy of the Walgreens website. A prominent heading: “Goodbye big, bad needle.” A footnote all the way down the page notes that testing could happen with a finger stick or venous draw. Mosley says he doesn’t remember seeing this language.
We’re returning to due diligence. Wade asks if Mosley looked at the Theranos website, and Mosley responds, “I can’t imagine that I didn’t look at the website.”
Kissinger is quoted in this Parloff article saying that “there is no performance associated with” Elizabeth, which is ironic, given that her public persona — the voice, the turtlenecks, the red lipstick, etc. — was such a huge part of the Theranos myth!
Mosley testifies that the article was “a very compelling story” that was “absolutely” impactful when he read it. Wade’s going through the article page by page.
We’re back to the Parloff article! Mosley sent it to the C.E.O. of the DeVos family office.
Holmes spoke on an hour-long panel called “Game Changers.” (Wade wanted to publish more of this document, which listed all of the different speakers at the 2014 BDT conference, but Judge Davila said it wasn’t relevant.)
We’re discussing an investor conference where Mosley met Holmes for the first time. Wade asks if Mosley would characterize it as a “Woodstock for private family offices,” the best line of the day thus far; Mosley declines but agrees that it was for “high net worth individuals.”
Wade is now talking about the Pfizer report. He has Mosley confirm that he thought Pfizer had written the report, but never actually directly asked whether Pfizer had.
Wade is asking about Mosley’s characterization of Theranos’s “national retail footprint,” noting that the Walgreens partnership was only in CA and AZ — seemingly trying to show that Mosley may have also overstated Theranos’s reach.
Mosley also wrote: “The most extensive evidence supplied regarding the reliability of the Theranos technology and its application is a Study Report prepared by Pfizer based on a clinical cancer treatment trial.” As we know, Pfizer didn’t prepare it.
We’re back to the memo Mosley wrote. He referred to a Johns Hopkins review that concluded that the technology “is novel and sound.” Mosley also noted the Walgreens partnership. Wade asks: Would you expect Walgreens to do due diligence? Mosley responds: Yes.
Wade is walking us through the binder Theranos gave Mosley to review. Included in the binder: a line claiming that “Theranos technology is able to perform the full menu of laboratory tests,” along with around 200 pages of supporting material.
Still, in a 9/2/14 memo Mosley wrote to Kissinger, he wrote: “There is substantial data and other information attesting to the quality, performance and reliability of the Theranos technology and equipment.” Wade highlights this line.
Wade asks Mosley to confirm that he hadn’t done substantial research into the company at this point, and Mosley counters that he doesn’t think he would have had a way to.
Mosley testifies that his 2014 analysis of Theranos came from printed materials provided by the company and his conversations with Holmes. Wade notes that Mosley didn’t mention media in his outline, but Mosley said he had “certainly” read media articles about the company.
He was also connected with the Oppenheimer family ($20 million) and John Elkann ($5 million), who were friends of Kissinger’s but not Mosley’s clients.
Mosley was VERY well-connected with Theranos’s investors. Per a slide entered into evidence, he was the attorney for the Walton family ($150 million invested), DeVos family ($100 million), Cox family, ($100 million), Andreas Dracopoulos ($25 million), Henry Kissinger ($3 million).
Good morning! I am back in the courtroom for the Elizabeth Holmes trial. After some pretrial arguments about whether testimony from a patient called BB should be excluded (no decision yet disclosed), the lawyer Daniel Mosley is on the stand to continue his cross.
The jury is dismissed for the day. Chaotic vibes today, between the guy who snapped a photo in the courtroom, a stifling 76 degree room and a worked up person in the hall bugging journalists about their parking dispute.
Mosley’s description of what he does at BDT is comically vague. “I’m involved in the management of the firm, I run the New York office. We advise and work with high net worth families and I do that type of work.”
I imagine this will be a contentious cross-examination. We’re already talking third-generation billionaires and levels of white shoe law firm prestige.
Theranos’s investment docs had a provision for mandatory redemption, i.e., the company could buy back shares at any price at any time. 🤔 Holmes reassured Mosley that wouldn’t happen.
We see a list of Theranos’s risks in Mosley’s memo to Kissinger. Prosecution asks why it doesn’t list the risk that Holmes could give inaccurate descriptions of her company’s technology. “I did not believe it was a risk,” he says.
Mosley testifies that he liked that Elizabeth Holmes’ shares in Theranos had 100x voting power of the other investors. “She was obviously a visionary that had created this company and developed the technology and having her in control of the company was a good thing.”
Mosley wrote a memo to Henry Kissinger about Theranos’s technology with a strong, strong endorsement. He believed fully in the conclusions from the pharma validation reports.
Byron Trott’s firm, BDT, threw a conference in Chicago in 2014, where Mosley introduced Holmes to the DeVos family, the Walton family and the Cox family — all clients of his.
We talk about the revenue projections and Schenk pre-empts the defense’s argument that projections are about the future and not supposed to be accurate by asking Mosley about that. Since it was October, Mosley expected the $140 million revenue projection for the year to be pretty close.
It is incredible how much mileage Holmes got out of one Fortune article. I think every investor who has testified said they read it. I guess prosecution keeps bringing it up because we know the author Roger Parloff will soon testify.
We run through the entire rigmarole we have now seen many times: listing out the specific and clear promises Theranos made to investors about its technology and the investor testifying they invested on that information.
We’re looking at illegible handwritten notes Mosley took and it feels like deciphering ancient scrolls
Holmes snail mailed Mosley a thick stack of presentations in 2014. We discuss lines like: “The company plans to be private for the long term.” “Theranos has grown from cash from its contracts for some time.”
The Web of Powerful Men goes on: We see an email where Mosley offers to connect Holmes to the Walton family. Mosley says Holmes wanted investors who were “high quality families.”
Next witness is Dan Mosley, a lawyer and guy about business. He invested $6 million in Theranos after Henry Kissinger, his client, introduced him in 2014. He now works for Byron Trott, Warren Buffett’s banker who was discussed during the DeVos testimony.
Theranos’s work with S-P fell off when the company merged with Merck. We see emails from Holmes to Cullen trying to move the validation forward with no response from Cullen. Kline make the final point that S-P never told Holmes about her concerns.
Kline, who is a lot folksier than Wade, asks Cullen to repeat that she never voiced her concerns with Theranos to the company because it was awkward. Apart from one email, is Cullen aware of any emails from S-P or Theranos asking for more information? “No.”
(Note: This was 2009.) “There was insufficient technical detail for us to be able to evaluate the technology.” She says Holmes answered almost exclusively, even questions directed to others.
Cullen testifies she never objected to the validation protocol. We see the invoice for Theranos’s work with S-P with the objective of “comprehensive validation of the Theranos cytokine panel under F.D.A./I.C.H. guidelines.”
Kline asks about the validation work that S-P did with Theranos was sufficient. “It hit the requirements, but at the end of the day, the execution would not have been in alignment with F.D.A. requirements for validation.”
John Kline is leading a cross-examination. Cullen testifies that S-P was impressed with the demo they did of one blood test on a Theranos machine they were given.
In the second version of this document, the conclusion adds the word “more” to the line about the results’ accuracy. Cullen says again she doesn’t agree with that conclusion. End of direct exam of Cullen.
We see the infamous validation report that featured Schering-Plough logo. Cullen says she did not agree with the report’s conclusions and no one at S-P said the docs were accurate.
Cullen says she didn’t say anything about it at the meeting because “um, it’s awkward.” Unfortunately I can’t see Holmes’s expression but I have a feeling if they run into each other in the bathroom later it’ll be even more awkward! 😬
Cullen adds that there were no direct answers to questions and the questions were fairly technical, so the answer should be fairly technical and direct. “There were what I’d describe as cagey responses or attempts to redirect to other topics of discussion.”
We see a calendar invite and agenda from a May 5 meeting. This was the first time Cullen met Holmes in person. Cullen said she asked many questions and “was dissatisfied, quite honestly, with the response to the questions.”
Peterson is excused. Next witness is Constance Cullen. Cullen worked at Schering-Plough. They asked her to participate in evaluating Theranos’s technology. They beta tested a few machines and she visited Theranos’s offices.
It’s usually pretty clear in the gallery who is a reporter and who is a member of the public. There are always a few people in suits who I can’t quite place. The guy who took a photo had a suit on. He is, unsurprisingly, not here now.
Uh… we went on a break because someone walked into the back of the courtroom and took a photo. That person is now being chastised by the judge.
Theranos told RDV in October of 2014 that it would do $140 million in revenue that year. It had zero. Prosecutor Robert Leach: “Did you in anyway dream that revenue for that year would be zero?” She says no, “projections should be somewhat close.”
Peterson pushes back: “You’re trying to measure our sophistication as an investor when we weren’t given complete information.” Wade moves to strike and Judge Davila tells Peterson to wait for Mr. Wade’s questions.
Wade shows Peterson the legal agreement for the investment and goes through all the normal disclaimers — projections can change, the investment was speculative, RDV (the DeVos firm) was accredited and sophisticated, etc. The “you should have known better” argument.
Some points of contention: When the investment decision was made. Whether Peterson had gone to Theranos’s website to see it advertised CLIA lab tests. What Theranos said about its military work. Comments Peterson made in prior depositions that contradict her testimony today.
Wade keeps asking questions meant to trap Peterson over prior comments, she keeps offering more detailed answers, Wade keeps striking her answers from record. After striking at least five, the judge scolds Wade: “Some of your questions are lend themselves to an explanation.”
Right out the gate prosecution objects to an email defense is using to refresh Peterson’s memory that she wasn’t on. Judge Davila: Anything can be used to refresh a witness’s recollection — a shoe, a sock…. Defense attorney Lance Wade: I’ll keep my shoes on, your honor.
🩸 US v. Holmes continues today with cross-examination of Lisa Peterson, who managed the DeVos family’s $100 million investment in Theranos.
Court for US v. Holmes is cancelled for today, broken water main. Back Tuesday! Weekly “wrap-up” of one day of testimony coming soon.
Now a court marshall is literally hovering over my shoulder watching and listening to me type. There is an overflow room but the sound is awful and unreliable. So.. .I think I will save my keystrokes for my own notes and limit my tweeting for the rest of today.
It went on and on, with Wade even reading notes from a deposition by RDV lawyers from years prior that used the term unicorn and Peterson insisting, “I would never use that word, unicorn.”
Wade: Do you know what a unicorn is?
Peterson: Can you explain it?
Wade: You’re the investment professional.
Peterson: It’s not something we normally invest in.
Fantastic unicorn content with defense and witness quibbling over the definition of a unicorn.
Lots of discussion about Dan Mosley, who was a lawyer at Cravath. Some documents were emailed via personal Gmail accounts, Peterson said, because “We didn’t know what his role was in all of this. We didn’t want to get him in trouble.”
Lance Wade (Holmes’s lawyer) is not playing nice with Peterson, grilling her on whether the DeVos family actually ever read her memos and her past comments under oath in depositions about that fact.
This is an interesting trojan horse to play the jury videos that clearly and succinctly summarize what we have learned so far about Theranos’s problems and also showing Holmes saying the buck stops with her – “I’m the founder and CEO of this company.”
Judge Davila has overruled objections to playing clips of Holmes on Mad Money and we are watching the part where she says “This is what happens when you work to change things. First they think you’re crazy, then they fight you, then you change the world.”
We are looking at Theranos’s revenue projections, including that bold $990m for 2015 (with a $230m profit). Peterson said she did not know that Theranos had zero revenue in 2013 and 2012.
Recall that a Pfizer exec testified it had nothing to do with that validation report. It never validated Theranos’s tech. But Theranos put its logo on the report and showed it to investors.
Prosecution shows Peterson the falsified validation report we have heard so much about. “Did you believe this report as prepared by Pfizer?” “Yes.” Peterson says that endorsement was a big factor in investing.
A familiar rundown of Theranos claims to investors. Its technology had been “comprehensively validated over the course of the last 7 years by 10 of the 15 largest pharmaceutical companies” and subjected to proficiency testing and audits from regulatory agencies.
We see a memo that hits this point again, stating that Theranos’s goal was to find investors “with less emphasis on liquidity and more emphasis on long term capital appreciation.”
“She was hand picking 5-6 private families to invest in her company. … She was inviting us to participate in this opportunity.” Peterson says Holmes didn’t want large PE firms/institutional investors b/c they wanted Theranos to go public and she wanted to stay private.
Interesting point about power dynamics of investing in high risk startup unicorns: “Did you feel like Theranos was selecting you as an investor?” Peterson: “Very much so.”
When Peterson’s team asked Holmes about the risks of investing in Theranos, she said the risk was in the “execution” of the Walgreens rollout. Was there a discussion of technology risk? Peterson says no.
We see an email from Jerry Tubergen, C.E.O. of RDV, to colleagues. He attached the infamous Fortune cover story, writing “This morning I had one of the most interesting meetings I can recall with the women profiled in the attached Fortune magazine article.”
Lisa Peterson has taken the stand and explained her role at RDV Corporation, the family office of the DeVos’s. She manages their PE fund investments and co-investments.
She asked to work on the Theranos deal bc she’d had some healthcare investing experience.
Needless to say this is extremely stressful for the media here. Members of the press now policing bystanders to follow the rules (silence phones etc) so as to not piss off the judge.
(First of all the juror who finds the typing distracting should really wear the hearing aids provided by the court. Second, this is a pandemic problem. Jurors are spaced out and some are sitting in the first rows of the audience.)
Ugh once again the jurors are frustrated with loud typing from the press gallery. The judge says if he gets another complaint he will banish all laptops to the overflow room. A court marshal is going to enforce the “silent keyboard” rule (WHICH IS NOT A THING!).
After her we will hear from Alan Eisenman, another investor.
Today’s first witness will be Lisa Peterson, who manages money for the DeVos family.
If there is one thing Judge Davila hates its getting into a “mini-trial” about side issues with no bearing on the issues being tried.
🩸 Elizabeth Holmes trial, Week 8 🩸
The lawyers are once again starting the day by fighting over evidence: Prosecution wants to show video clips of Elizabeth Holmes defending Theranos on Mad Money and elsewhere after the WSJ expose.
Cross-examination wrapped up. P.S. Sounds like we’re going to start doing bonus trial days on Mondays. All blood all the time!! 🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉🩸💉
Defense asks whether the reputation of Don Lucas, the partnership with Walgreens, its patent portfolio and its big name board members were factors in his decision to invest. Tolbert says yes.
The call in question was actually with Chris Lucas’s investment fund and Holmes was only on part of it. Defense plays a part of the tape where Lucas explains a stock split that gives Holmes full control: “She has a firm grasp on the company — let there be no mistake.”
In many ways this trial boils down one central tension which is playing out in this cross-examination: Were these investors fools who did not do proper diligence? Or was their diligence tainted because Holmes fed them bad info?
I’m not sure how well this clip actually makes the defense’s case, since she immediately says the investment money will allow them to pick up work on those projects “in parallel.” Defense hits Tolbert for not asking following up questions after the call.
On cross-examination, defense replays some portions of the investor call. In this one, Holmes discusses how Theranos was pausing its work on military and pharmaceutical projects in order to focus entirely on the retail rollout.
We’re now going through the technical process of describing how Hall Group wired its investment money to Theranos. This is, after all, a wire fraud case.
One thing mentioned on the investor call which has not been addressed — Holmes noted that there were some early investors who were looking for liquidity. Wonder if we will learn details about whether anyone cashed out along the way and who they were.
Tolbert says Theranos’s purported military work was a big part of why he invested because it spoke to a greater mission. “Theranos wasn’t just about an opportunity to make money … but to do so in a way that was beneficial for lots and lots and lots of people.”
I.P.O.? Theranos has a very long-term mind-set. “We plan on doing this for the next 20-30-40-50 years.” Military? Confidentially, it’s “a big deal for us.” Competition? That’s why we’re so secretive. How are prices so low? We are transforming the care process, ergo savings.
We listen to a long recording of Holmes answering questions from investors about when the company will go public, whether it works with the military and its competition. Her answers, as the Pfizer guy eloquently put it, are “non-informative, tangential, deflective and evasive.”
In the recording, Holmes says Theranos was growing on “cash from operations,” a.k.a. profitably, since 2006. Tolbert testifies he believed the proceeds of the 2013 fund-raise would be used for retail expansion — not R&D or tech development.
I forgot to tweet that another juror got dismissed today for cause. Kinda worried I’m bad luck, every time I come back from missing a few days of the trial, another one bites the dust.
In a third recording, Holmes describes fund-raising — in 2013 Theranos issued shares at $75 a share, up from 82 cents a share when Hall Group and Chris Lucas’s firm first invested in 2006.
In a second recording, we hear Holmes describing the way Theranos disrupts traditional phlebotomy with its finger prick tests. Tolbert testifies that that is why he invested.
We’re going until 4 p.m. today but I doubt we get to three let alone four witnesses. Tolbert testifies about the clip we just heard and his impression of what he thought Theranos was actually doing. (Blood testing machines — not a central lab.)
Holmes glanced verrrrrry briefly over to the jury after the recording. Otherwise sitting up stick straight and not moving, as usual.
Unfortunately I am not able to see the jurors’ faces upon hearing Holmes’s voice for the first time. In the recording, she is giving the usual pitch about Theranos’s big vision of creating “the largest lab in the country” and to “change the reality of lab testing today.”
We are going to listen to some recordings of a call Holmes had with investors. Before introducing them, Schenk, the prosecutor, asked Tolbert if he had had the chance to “observe” Holmes’s voice in meetings and on the call. 👀
In 2013, Hall Group invested $5 million into the company. The company had around 10 days to decide on the investment and the share price had jumped to $75 a share. Tolbert recorded a pitch call with Holmes. He said he’d been frustrated about not having a lot of information about Theranos.
We see an email from Chris Lucas to Hall Group in 2013 about Theranos adding board members. It says “Hopefully, this also means we will start receiving more communication from the company.” Tolbert said he’d been wanting more visibility into the company.
Theranos also had promised investors it would go public in 2008. 🙃
After that, in 2006, Tolbert decided to invest $2 million via the investment fund of Don Lucas’s son Chris.
Tolbert had dinner with Holmes and Lucas where they talked about Holmes’s vision and also “heard some fun stories from Don Lucas about his investment career.” He also visited Theranos’s office and someone gave him a cartridge.
We see a detailed financial projection from Theranos that shows the company becoming profitable in 2007. (Narrator: It did not…)
Point for team “Theranos is not a Silicon Valley company because it didn’t raise from traditional venture capitalists”: Hall Group was primarily a real estate investment firm. Counterpoint: Hall Group was introduced to Theranos by Don Lucas.
Next witness: Bryan Tolbert of Hall Group. The firm invested $5 million in Theranos in late 2013.
On cross-examination of Shane Weber, Holmes lawyer John Cline hammers the point that Weber did not send his report about Theranos to Holmes. The point (I assume) being that, without seeing the report, Theranos had every reason to keep thinking Pfizer liked its technology.
That’s it for direct.
Did Pfizer and Theranos have any meaningful business dealings after 2010? No. Do you agree with statement that Pfizer validated Theranos’s technology? No I do not. You came to the opposite conclusion? I did.
A funny thing about TV trials is that they explain the objections in normal language but in real life they say things like “objection, this is 702 territory” or “same 406 from last time your honor.”
We get a side by side of the report, one with Theranos logo on it and one with the Theranos and Pfizer logos on it. Would it be fair to say in 2010 or after that Pfizer endorsed Theranos’s technology or comprehensively validated Theranos’s technology? Weber: “No”
Now we see an email from Walgreens to Pfizer, which includes the validation report I mentioned above where Theranos put Pfizer’s logo and implied its approval. Weber said he hadn’t seen this before the feds showed it to him.
Weber called Elizabeth Holmes to tell her Pfizer wasn’t going to work with Theranos. In an email to a colleague, he said “I was polite clear crisp and patiently firm as she pushed back.” Writes that Holmes asked for other names at Pfizer to talk to and he “politely deflected.”
The document further lists six technical due diligence questions that Weber asked Theranos execs on a phone call, and concludes their answers were “oblique, deflective or evasive non-informative answers.”
Most of Weber’s answers have been very technical and full of jargon sure to confuse jurors but that list of adjectives hits pretty hard. (Defense tried to object.)
Further in his summary, Weber says Theranos’s conclusions are “not believable” and calls the company’s answers to due diligence questions “non-informative, tangential, deflective or evasive”
(Recall that last week we saw a document with Pfizer’s logo on it that implied that the company validated Theranos’s technology, which Holmes used to solicit investment from Walgreens and others)
After talking with Elizabeth Holmes and reviewing a bunch of documents (including a patent), Weber created a summary report on the use of Theranos technology. Believe this is the report the defense didn’t want shown to jurors, and the judge allowed Page 1. Weber’s recommendation: “Theranos does not at this time have any diagnostic or clinical interest to Pfizer.”
We begin with a series of emails establishing why Weber was involved with Theranos at Pfizer — his role was to make a recommendation to the company about its technology. “We were looking for diagnostic capabilities that would open the door for more effective intake of patients.”
The U.S. has called Shane Weber, who was a scientist at Pfizer. He is speaking loudly and clearly into the mic and for that I thank him. 🙏
Sounds like we’ll be hearing from our first investor (aside from Walgreens): Brian Tolbert of the investment firm Hall Group is likely to testify today.
🩸 Back in court for the fraud trial of Elizabeth Holmes. It is rainy, the prosecution plans to call four witnesses today, and the press corp is typing every so carefully after being scolded for distracting a juror with our keyboards.
As usual, we are starting late because the lawyers are fighting over admitting a document and there is an issue with a juror.
Edlin is excused, and we are breaking for the day. Erin Griffith will be in the courtroom on Friday when trial resumes.
Edlin on his choice to leave: “In the year after the initial WSJ articles came out, the company claimed that it would be able to prove that the technology worked and prove that those claims were not true. The company was unable to convince anyone that those claims were untrue and that its technology and science worked. That gave me serious doubts as to whether the company was capable of proving its technology worked.” He came to the conclusion they would never be able to prove it, he said.
Bostic: At Theranos, whose decision was it to disclose what information to the press? Edlin: In my experience, Elizabeth was the only person who communicated directly with the press. Bostic: Did anyone make decisions about what she was allowed to say? Edlin: I don’t know if she consulted with anyone.
Bostic: Who did the final review of investor presentations? Edlin: Elizabeth.
Now, looking at when Holmes weighed in on website language, asking to say a 4-hour window rather than 2 hours. Rather than addressing this, Bostic seems to be pointing out that in other cases (including website/investor presentations), language around “superior accuracy” made it in.
OK, and we’re now back to an email Downey brought up, where Holmes wants to put the language around the venous draw in the main body of text. The language she wanted called venipunctures “uncommon.” Bostic points out that venous draws were used in 40 percent of the time at Walgreens.
Bostic: Who had final say over what results were reported in the demo? Edlin: Daniel did and Elizabeth did.
Bostic: Was part of that a desire to show that the technology performed well? Edlin: Yes. Bostic: How is this purpose served by hiding errors? Edlin: I don’t know. Bostic: What about withholding results? Edlin: I don’t know.
Rapid-fire questioning from Bostic just now. Edlin: The purpose of the tech demonstrations was to “showcase or demonstrate the Theranos technology. In some cases, tests were run. In others, tests weren’t run. In general, to show the functionality of the Theranos technology.”
Back from break, and Bostic says he has around 30 minutes left of cross-examination. Downey says that we’ll finish with Edlin today. We’re now looking at a document regarding the Limited Objective Experiment with the U.S. Central Command, which Edlin testified again did not occur. Completion of this study was a prerequisite to clinical use of Theranos devices by the military, Edlin confirms.
Downey wraps cross, and Bostic is back for redirect. We’re starting with the relationship with the military. Bostic notes that only 28 people participated in the burn study. Edlin also doubles down on his previous testimony that the military never used Theranos devices on soldiers.
Looking at another email about the brochure for Walgreens, where Christian Holmes is relaying feedback from Elizabeth. Throughout cross, Downey has brought up emails/instances where Elizabeth has advocated for transparency and disclosure to counteract what we saw in direct.
Back from break and looking at a presentation Edlin helped prepare for an investor. In an email questioning the accuracy of a claim in one graph, Holmes wrote: “If they currently do refrigerate then we should reflect that so we are making an accurate claim.”
Downey is trying to establish that the use of the demo app, brought up by the government, isn’t deceptive/malicious, pointing out that someone may show up and not get their blood drawn and that there were different protocols for different scenarios.
Downey is discussing the demo app, which as shown before shields failures from the patient. “You were not trying to deceive anyone in this demo process, correct? And you did not understand that anyone else at Theranos was trying to deceive anyone in this process?” Edlin agrees.
Shifting topics to demos, after around an hour of questioning about Theranos’s military relationship. Around 10-15 people worked on the team to do demos, with Daniel Young reviewing and approving all demos, Edlin testifies.
Givens wrote that the machine “seemed to function well in the environment,” and her only complaint was the touch-screen. She wrote that she hoped to get funding for a full proposal.
Downey is bringing up emails from Melissa Givens of U.S. Africa Command and former Theranos V.P. Daniel Young indicating that the device performed well in high temperatures in Africa. Yesterday, the government showed evidence saying that the devices couldn’t operate over 82 degrees.
Good morning from San Jose! Daniel Edlin is back on the stand. We’re still expecting former Pfizer diagnostics director Shane Weber next.
We’re breaking for the day. I’ll be back tomorrow at 9 a.m. for more of Edlin’s cross-examination.
Downey asks Edlin a series of questions around whether he ever took steps to put forward any claim he knew to be false. Edlin says repeatedly that he did not. “That information was reliant on information you had gotten from scientists in the company, correct?” “Yes.”
Downey started by having Edlin confirm that he was not a tech expert — Edlin majored in public policy at Duke.
And — defense changes the subject completely. We’re back to talking about Theranos’s technology as we begin cross-examination.
With that, we’re through with direct and onto cross. Testimony is scheduled to end at 3 today, so Edlin will likely continue tomorrow.
Edlin said he was in meetings where Balwani said he would defer to Holmes. “Generally, she was the C.E.O., so she had the final decision-making authority.” Edlin said he saw them disagree about “certain topics.” When they disagreed, Edlin says there wasn’t always a decision that was made. He saw times when Balwani would defer to Holmes but can’t recall the reverse.
Back from break. Bostic is pivoting to what Edlin observed of Holmes and Balwani working together. Holmes and Balwani had offices next to each other with glass walls. They often ate lunch together and were in discussion together, he said, but nothing else stands out.
We’re going through slides approved by Holmes and sent to the military for a 2012 burn study. After many claims, Bostic asks Edlin whether he knew at the time whether this was true or not. Edlin says repeatedly he didn’t know, but he had no reason to doubt it. One exception: One bullet read that most results could be obtained in less than 20 minutes, but Edlin testified that demo run times were usually longer than 20 minutes.
In the doc: “Theranos has created a point-of-service laboratory infrastructure that generates real-time data from a finger-stick of blood or other micro-volumes of different sample types delivering higher quality data than previously possible.” Also: “Each Theranos device can run every test currently available through the traditional centralized or hospital laboratory infrastructure.” Edlin testifies: “I had no reason to believe it wasn’t true.”
We are now looking at a document that was sent to Major Steven Cook. “Everything in this document was reviewed and approved by Elizabeth,” Edlin testifies. Holmes was highly involved in every discussion/email communication he had with the military, he says.
Switching topics to Theranos’s interactions with the military. Edlin helped support Theranos’s military and D.O.D. relationships. “The end goal for these communications was to set up a research program that would compare Theranos testing to the testing available to the military.”
Edlin testifies that he doesn’t remember Holmes asking him to take out language like this from investor binders, and says that he remembers presentations like this being sent to other investors as well.
Under the heading “Same Tests, a Whole New Approach”: “The actionable information you need, 1/1000 the size of a typical blood draw.” This page also says “the highest levels of accuracy and precision.” Theranos’s attorney flagged this language in conjunction with the website.
Included in a binder sent to Rupert Murdoch: “Theranos’s proprietary, patented technology runs comprehensive blood tests from a finger-stick and tests from micro-samples of other matrices, and generates significantly higher integrity data than currently possible.”
Edlin testifies that he would prepare binders for investors. “Elizabeth asked to review them and once they were reviewed and approved … I would send them to investors,” he said.
Bostic shows Edlin the purported Pfizer/Theranos study report, but Edlin doesn’t know who created it or put the logo there, he testified.
The marketing on Theranos’s draft website included “a tiny drop is all it takes” and “highest level of accuracy.” In a four-page email, Theranos attorney Kate Beardsley raised accuracy questions about some of this marketing, in some cases asking for substantiation or suggesting changes (i.e., “full range” to “broad range,” “highest quality” to “high quality”).
Edlin testifies that Holmes was “very involved and detail-oriented” in reviewing and approving Theranos’s marketing. “For the end product, and for what actually went onto the website, she did review that.”
Dec. 27, 2015, email from Holmes regarding a “VIP guest”: “You can say we do run those assays, but were not able to run them on this sample, apparently due to a human error in sample handling.” However: We just saw an email from a Theranos scientist saying it was not human error. This email was in regards to a Forbes writer who planned on writing about his experience.
Regarding those results: Bostic enters a Jan. 7 email from Tina Lin to Edlin, noting some issues with the results (some high, some low). “We have no sample for rerun since it was a short draw,” she wrote. Theranos began testing in wellness centers over a year ago, Bostic notes.
Jumping ahead to the Murdoch investment. Jan. 6, 2015, from Holmes: “I [sic] would be an honor to have you be part of our company.” Jan. 7 from Murdoch: “Thanks, Elizabeth. Enjoyed every minute of it. Any blood results? See you soon, Rupert”
Email from Edlin: “Unfortunately by the looks of the Thyroid panel results below it appears to have had major issues again.” Balwani: “To say this is deeply disappointing will be a gross under statement.” This was about a month before the public launch, Edlin testifies.
We’ve spent the morning so far looking at different email chains in which Daniel Young instructed Edlin to change or remove abnormal test results from demo reports. Holmes has been included on many of these emails.
The jury is seated, and Daniel Edlin is back on the stand. We’re starting again with a recap of Theranos demos. Last Friday, we discussed how they used the “demo app,” which shielded device failures from view, or the “null protocol,” which wouldn’t actually analyze the sample.
Good morning! I’m in the courtroom in San Jose. We’re starting with Daniel Edlin, a former senior product manager at Theranos (and college buddy of Christian Holmes). Based on pretrial arguments, we’ll have former Pfizer diagnostics director Shane Weber next.
With that, we’re breaking for the weekend. We’ll pick up with Edlin on Tuesday.
We’re looking at an email chain between Edlin, Daniel Young, Michael Craig and others, preparing for a tech demonstration. They decide to go with the demo app, which “shields protocol failures from the client,” Craig wrote. If an error had taken place, it wouldn’t show on the screen that an error had taken place. It would say running or processing, Edlin said.
Edlin conducted trainings for Walgreens staff and would give tours around Theranos. “In advance of the tour, there were some areas of the labs that were hidden by a partition” to conceal Theranos devices, Edlin testifies.
Edlin was aware at the time of Theranos using modified third-party devices to run venous draws but did not know the third-party devices were used for fingerstick draws until 2016.
Edlin worked on the “front-end customer experience” for the Walgreens partnership, including the store’s branding and marketing as well as software used by patients and technicians. Edlin testifies that he was familiar with the Edison machines (3.0 and 3.5), the MiniLab, and the Edison 4 series (the next-gen version of the Theranos devices). The next-gen versions were never used for clinical patient testing, he testifies.
So far, Edlin has testified about Holmes’s work habits — she was in the office “all the time,” from early morning to late evening and on weekends — and about how information was kept siloed within Theranos, on instructions from Elizabeth, Christian and Sunny.
Edlin was recruited to Theranos by Christian Holmes, who Edlin describes as “one of my closest friends.” He first met Elizabeth Holmes through Christian while Edlin and Christian were at Duke.
Daniel Edlin, a former senior project manager at Theranos from 2011 to 2016 who worked directly with Holmes, is on the stand.
After a break, we’re back in session. There may be more disruptions coming up to the trial schedule: A juror’s mother-in-law passed away suddenly and she may have to travel to the Midwest, and a friend of Davila’s is critically ill.
Redirect is done, and we are back to re-cross. After some back and forth on Dhawan’s assumptions that Theranos employees were doing their jobs, Dhawan has been excused.
The government is asking about Lynette Sawyer. Dhawan says he didn’t meet Sawyer and doesn’t know whether she went into the lab or saw the Edison. In general, the government is working to show that Wade’s line of questioning relied on assumptions.
We’re through cross and into redirect. Wade’s cross-examination stayed on the same theme: that Theranos had plenty of qualified employees, and Dhawan’s minimal presence in the lab wasn’t a concern.
Wade is pointing out that Dhawan, as a part-time employee, delegated his responsibilities to different full-time Theranos employees. “No one was pretending you were there every day,” Wade continued. “You were there as needed, right?”
Lance Wade is starting with discussion of Dr. Lynette Sawyer, who also served as a part-time lab director during this time. Dr. Sawyer did not come up during direct yesterday — Wade seems to be arguing that Dhawan didn’t do much because Sawyer was handling more of it.
After a juror overslept, we are finally starting testimony in “Our Holmes Matter” in San Jose. We’re starting again with Dr. Sunil Dhawan, who became lab director after Adam Rosendorff left.
Motion to compel is denied, Parloff is not required to turn over his notes. Judge said it doesn’t even have to get into the issue of reporter’s privilege because the defense hasn’t made a strong enough case for it. “It’s a fishing expedition.”
We’re wrapping for the day. I’ll be back in the courthouse at 9 a.m. tomorrow when the trial resumes.
Parloff counsel David Korzenik: “The trial is not about Mr. Parloff’s state of mind. It’s not a libel case against his subsequent article in which he corrected his first.” “He can only testify as to what Ms Holmes told him.”
Wade is asking about Dhawan’s interactions with Holmes and Balwani. Wade says that Balwani was running the laboratory from an operational standpoint. Dhawan says he can’t comment on that, but his assumption was that he was.
With 15 minutes to go today, we’re starting in on cross-examination. Wade (who spent days on the stand cross-examining Rosendorff) is starts by establishing that Dhawan is a highly trained professional.
Dhawan says he doesn’t recall ever asking questions or asking a report to be changed. He also signed a document about reporting of critical values without ever seeing a critical value.
Rosendorff had signed the documents before Dhawan did. “It gave me some reassurance that there had been some supervision before my time of arrival,” Dhawan testified. Dhawan signed the validation for the Edison without ever seeing it run anything.
Also, “We want to show the information he was pointed to. It doesn’t matter if it turns out to be correct or incorrect.”
Onto the Parloff matter. Cline says the Holmes camp wants to Parloff’s reporting notes in order to show that Parloff “was colored by bias — a desire to blame any errors he made in his initial article on Ms. Holmes rather than” his own errors. Wow.
The magistrate judge grants motion for the exclusion. “He’s testifying as to secondary things. He’s reporting and testifying about something someone else said or did that he covered. He really is akin to an expert witness who has collected information from many sources.” Carreyrou is now allowed to be in the courtroom.
The Q.C. manager, Langly Gee, introduced himself to Dhawan in August 2015. He wanted Dhawan there for the CMS audit on 9/22/15. Dhawan said he was there for the audit. Before that, he said he signed “whatever was sent to me.”
Dhawan did not go to Theranos every day. He went to Theranos twice. He didn’t interact with patients, physicians or Theranos lab employees. He never dealt with Q.C. He thinks he worked 5-10 total hours from November 2014 to June 2015. For this, Dhawan was getting paid $5,000 a month.
Cline: “I understand this is a hardship for Mr. Carreyrou. He’s not the only one suffering a hardship. Ms. Holmes’s father is a witness. We may call him. He’s having to miss the trial of his daughter.”
Prosecution notes that it already brought a motion to block any arguments that there was coordination between the government and Carreyrou. Says there is no evidence of that and that Judge Davila already agreed to block such arguments.
Will the Holmes camp call Carreyrou as a witness? Holmes lawyer John Cline: “I can’t tell you at this point who we’re going to call as witnesses. We may. We may not put on a case. We may call Ms. Holmes. … I can certainly tell you we may call him.”
As expected, we are now calling Dr. Sunil Dhawan, a dermatologist who became Theranos’s lab director after Rosendorff left. After several days on Theranos’s partnerships with other companies (Safeway, Walgreens), we’re now back to internal Theranos workings.
After brief re-cross from Downey, Jhaveri is excused.
He adds that any subpoena issued to Carreyrou would be in bad faith or harassing. One example: “Ms. Holmes leading her employees in a chant that says F You, Carreyrou. Obviously I’m abbreviating that.”
Carreyrou lawyer: “We believe he’s being singled out because of his prior reporting and because of the animus Ms. Holmes has for him.” Lawyer also says it’s a matter of First Amendment rights.
Schenk is up for redirect. He notes that the patient experience surveys were before they got their test results, so if they, for example, were told they were not pregnant but were in fact pregnant, that would affect their experience but wouldn’t be counted in survey results.
Judge: “I’ve not been following Mr. Carreyrou’s podcast, but as I understand it he’s been able to report on what’s going on and comment on what’s going on.” Judge asks what’s the problem?
On the Carreyrou matter, the magistrate judge suggested that he be categorized as an expert witness, “a pragmatic solution,” he said. Holmes side said (understandably?) that that doesn’t make a lot of sense.
Defense has tried to compel Parloff to release his notes. Some of them (old emails) no longer exist. But others would involve forcing him to turn over notes and sourcing, etc. He already provided some recordings of interviews to both sides but is fighting the subpoena for notes.
They’re also going to be dealing with the motions involving Roger Parloff, who wrote a Fortune cover story that is literally being discussed in trial at this moment.
While testimony is happening, there is also a separate Zoom hearing now with a magistrate judge, Nathanael Cousins, over whether the journalist John Carreyrou will be allowed in the courtroom.
Looking at a January 2015 patient experience survey summary. Patients rated the overall experience as 4.81/5 — more support for Downey’s line of argument here.
In general, Downey seems to be taking a very reasonable, friendly tone with this cross-examination (in contrast, for example, with the way Wade started off cross with Rosendorff two weeks ago). Main points: opening stores is hard, but patients were happy.
Downey is really trying to highlight patient satisfaction to show that the partnership was a success. Jhaveri pushes back, saying that patient experience was one important factor, but so was cost of build-out, venous draw percentages, etc. Jhaveri does concede that he doesn’t remember getting negative feedback about the tests being done in venous draw form.
Other documents showed that Walgreens didn’t include venous draw percentages among “key program risks” and that Jhaveri told Walgreens colleagues not to discuss future market expansion plans outside California and Arizona.
Downey highlights documents that make the case that the partnership was doing better than the government painted it as. We saw a set of Walgreens/Theranos meeting minutes saying that patient experience surveys were “off the charts.”
Downey establishes that Jhaveri had very little contact w Holmes; Jhaveri says he met with her “two or three times at most.” (His main point of contact was Balwani.)
Back from break. Downey is starting cross with questions about how opening stores is a difficult job.
After reading the texts, the government finished its direct examination of Jhaveri. We’ll pick up with cross after the break.
Here’s the full document with 36 pages of texts: https://www.documentcloud.org/documents/21081045-holmes-balwani-texts
Text messages between Holmes and Balwani about Walgreens! Jhaveri and Schenk are, for whatever reason, taking turns doing a live reading. (Jhaveri is Balwani; Schenk is Holmes. This does indeed feel kind of like high school English class.)
In 2015, venous draw percentages never went down enough to expand beyond 40 stores in Arizona and one in Palo Alto. Balwani’s explanation for the percentages never changed. Then, in late 2015, Jhaveri testifies, he read a negative article about Theranos. Walgreens stopped offering Theranos tests in 2016.
General theme of Jhaveri’s testimony thus far: Theranos wasn’t hitting its targets regarding venous draw percentages, but Jhaveri was willing to keep working with them. But, the government notes: What Jhaveri didn’t know was that Theranos was not doing testing on its own devices.
8/15/2014 email from Jhaveri, where he wrote that “we have made unbelievable progress in the short 5 months.” Jhaveri still believed that Theranos was doing testing on its own devices, he testifies. In the same email, Jhaveri wrote that he wants to focus on improving patient experience and “venous percent in the 10% range.” At that point, it was still around 40%.
Now looking at revised goals from August for the Theranos partnership. For F.Y. 2015, they were now aiming for 200 stores instead of 500, based on the results of the pilot. The venous draw percentages and the cost of the buildout were two reasons for the reduced goals, Jhaveri testifies.
In June 2014, Jhaveri still thought that Theranos was doing its testing on Theranos devices. He did not know that Theranos was testing patients’ blood on modified third-party devices. And no one, including Balwani, was satisfied with the venous draw percentages.
When Theranos did a finger stick draw, Walgreens thought that blood was being tested on a Theranos device. Walgreens did not know it was being tested on a modified commercial device, Jhaveri testifies.
Walgreens agreed that some, more complex tests might always require venous draws, but those tests were supposed to be less common. A slide attributes the “higher number of venous draws so far” to “learning process around ordering patterns for Arizona,” not tech problems.
The percentage of finger stick draws was “very important,” Jhaveri testifies. “That was the Theranos technology that we had signed a partnership on. … That was the actual magic that was so intriguing to us.”
Patients could receive traditional lab work via venous or finger stick test. Traditionally, labs would do venous draws. Theranos, as we know, promised to do the same tests on a small amount of blood through a finger stick, which Jhaveri calls “extraordinary.”
At the time, Theranos was in one store in Palo Alto and two in Arizona. They were tracking customers’ wait time and experience level. They were also tracking some lab measures, including proportions of venous vs. finger stick tests.
Jhaveri was working to “operationalize” the Theranos partnership — expanding the partnership from the three stores it was in at the time. This included construction, design, layout, training, customer experience.
In early 2014, he became divisional vice president of health care services, and the Theranos partnership became part of his responsibilities at this time.
He re-engaged with the Theranos team at the end of 2013. At that point, he was still working on the new pharmacy design and wanted to figure out how the Theranos partnership would fit into the experience/construction of the store.
He first heard of Theranos in 2010, when he was leading a project to redesign Walgreens pharmacies to be more customer-centric. He met Holmes and Balwani when he gave them a short tour of a Walgreens store.
Jhaveri worked at Walgreens for 29 years (1989-2018). He’s a registered pharmacist with an MBA in organizational management.
We’re done with direct examination. On cross (which takes approximately one minute), the defense establishes that Amenta didn’t have special knowledge of the wire transfers beyond knowing that they occurred. And we are now done with Amenta and onto Jhaveri.
Prosecutor John Bostic is taking Amenta through federal wire transfers sent to Theranos, presumably to show that wire transfers were made.
Jurors have filed in. Amenta is on the stand.
Back in the courtroom for a special Thursday edition of the Elizabeth Holmes trial! Today’s expected witnesses: Robert Amenta, deputy chief investigator at the Federal Reserve Bank of New York; Nimesh Jhaveri, a former Walgreens executive; and Dr. Sunil Dhawan, a former Theranos lab director.
That’s it for today. There will be trial tomorrow and one of the witnesses will be Nimesh Jhaveri, former head of health care services at Walgreens.
The next witness is Robert Amenta, deputy chief investigator at the New York Federal Reserve. We just walked through an explanation of what the Fed does. U.S. Attorney John Bostic: “So it’s a bank for banks.”
In 2015, after the WSJ Theranos expose, Miquelon wrote an email to Holmes: “You are in my thoughts, hang in there. The haters are everywhere but your contribution to the world cannot be bottled up.”
Defense makes the case that Walgreens entered into its agreement with Theranos knowing it did not have F.D.A. approval. Walgreens had the right to terminate the partnership if Theranos did not get F.D.A. approval by the end of 2010. (It did not, and Walgreens did not terminate.)
On diligence, Miquelon says: “I would define diligence as unfolding over a couple of years — diligence continues and that’s one reason why you have a revised agreement and addendums to that.”
Downy made the point that many of the promises Holmes made about Theranos’s technology were made when the company planned to put machines in stores. Idea being that those promises are irrelevant because Theranos decided not to put machines in stores, but test in its own lab.
On cross-exam, Holmes lawyer Kevin Downey is building up how big of a deal this effort was to Walgreens. Miquelon said Walgreens hired a firm to come up with a list of 180 start-ups working on lab development, which the company evaluated.
The fee hinged on the partnership hitting certain milestones, but in August 2013, Holmes emailed Walgreens asking to accelerate the payment and send the money sooner.
WOW this might be public info but I wasn’t aware of it. Walgreens paid a $100 million “innovation fee” to Theranos for the privilege of partnering with them. The actual investment in equity only came in the form of a $40 million convertible note.
🩸 After a two-hour delay caused by jurors raising issues about their questionnaires being made public, testimony in the Elizabeth Holmes trial (or, per the judge, “Our Holmes Matter”) is beginning with Wade Miquelon, former C.F.O. of Walgreens.
Miquelon describes the art of credibility trading — in an email selling Theranos to his colleagues he notes Larry Ellison’s endorsement. The prosecutors also make the point that Theranos was seven years along — pre-empting the “just a young start-up” defense.
We’ve seen several documents from pharma companies endorsing or validating Theranos’s technology. I believe these are the same ones we saw in the opening arguments, which were a pretty big smoking gun. The testimony hasn’t yet discussed whether they were falsified.
Miquelon offers a very familiar story by now: He was excited by the promise of Theranos’s technology. Lots of cheap tests on a finger stick of blood. We also know by now that witnesses must be very specific about the claims Holmes made because defense will pick them apart.
The next witness is the former Walgreens C.F.O. Wade Miquelon (now C.E.O. of Jo-Ann Stores).
Burd draws the line at revenue and profitability. “If you’re hitting strong revenue dollars relative to size and you’re making money, I would say you’re on your way.” (If they had asked me, I would have defined a start-up as a private venture-capital backed company.)
On redirect we discuss the definition of a start-up, rebutting defense’s claim that Theranos was just a tiny upstart dealing with a big bad corporation. “Do you differentiate between a start-up that is 7-10 years old vs one that is just starting out of a garage?”
Downey trying to make the case that Safeway’s stock had had a big drop between prior to Burd leaving. He does not take that bait. “In 20 years, that happens frequently.”
We go back and forth over the Theranos lab set up as a test on Safeway’s corporate campus. Burd was frustrated that it was supposed to have a “box,” one of Theranos’s blood analyzers, but for “secrecy” reasons, didn’t get one. Eventually it was shut down.
Downey has grilled Burd on the legal details of their partnership that gave Safeway exclusivity rights, paybacks, etc. on whether there was ever a hard deadline given for the launch.
A lot of focus on the diligence that Safeway did on Theranos and its technology. Burd spoke with various doctors and lab directors at Johns Hopkins, who said they had not had the Theranos machines long enough to validate them. “The box was taken back by Theranos.”
Kevin Downey, Holmes’s lawyer, is now cross-examining Burd. Building up all his experience, expertise, sophistication, etc., to compare with Holmes and Theranos. “You knew at the time that she was a very young entrepreneur. … And you knew the company was a start-up?”
Just email after email from Burd to Holmes expressing disappointment. “We are so good together when we collaborate, but I have never been more frustrated. I want to help, but you are making it difficult.”
Burd emailed Holmes: “I can recall getting discouraged once is (sic) the last 61 years. That said I am getting close to my second event.” Do C.E.O.s always email each other this way?
Burd emailed Holmes complaining about delays on launching Theranos tests inside Safeway stores. “I feel like a jogger running in place waiting for the stop light to turn green.” Another email has the subject line “Becoming Discouraged.”
Burd emailed Holmes in 2012 expressing concerns about a Theranos lab on Safeway’s campus. “I am genuinely concerned that Safeway’s lab reputation gets worse by the day.” He warned that if the problems continued for the soft launch, “both our brands will be at risk.”
The judge called the case “Our Holmes Matter” which I’m going to start using. Steve Burd, the former C.E.O. of Safeway, is back on the stand for direct examination.
🩸 In court again for U.S. vs. Holmes.
Thus concludes the Theranos trial action for the week. The trial is on recess on Friday, will be back on Tuesday.
He continues: “I’ve had the privilege of meeting four U.S. presidents. When the president is in the room — let me tell you, the president owns the room. No one talks unless spoken to. Her style was warm, it was friendly. It wasn’t dictatorial.”
Burd is highly complimentary of Holmes. “Not all C.E.O.s are alike. She would rise to the top of the pile in terms of vision, in terms of command of the information, clearly in terms of delivery. She was always decisive.” “Whenever she was talking she owned the room.”
Safeway initially negotiated an $85 million partnership with Theranos, including investing $30 million to install labs in its stores, which he said turned out to be a low estimate. The deal was negotiated directly with Holmes with no lawyers, which Burd found was unusual.
Now discussing convertible equity notes! Isn’t this is so much more fun than chemiluminescence and assays. 📈
Ooooooooh I think we just got our first mention of EBITDA in the trial, I can see the thrill of learning about accounting on the faces of these jurors.
For some reason he is talking about a strain of watermelon called a Pureheart that has a very small rind that Safeway sold exclusively for a year. 🍉
Rosendorff’s testimony is finally over. Steve Burd, the C.E.O. of Safeway for 20 years until 2013, is now testifying. When he heard about Theranos he was “immediately interested in meeting Theranos, particularly the founder.” “It was a fascinating concept.”
Defense counsel Wade is almost giddy to argue that prosecution asked Dr. Rosendorff to compare issues at Theranos to other labs he worked at. Defense should be allowed to bring up other investigations at labs the Rosendorff later worked at, he says.
Judge Davila says no, that would be a separate “mini trial.” He adds, “I think it may actually enhance the damage you’re seeking to avoid but, hey, it’s your case.”
Regarding the accusation that he stole trade secrets by emailing himself files, prosecution asks, “Based on what you know about Theranos’s methods, would you have wanted other labs to use those methods?” “No.”
For the last hour we’ve been hearing redirect on Dr. Rosendorff. For those counting, this is Day 6 of his testimony. The reason he left Theranos: “It was about patient care and my integrity as a physician.”
Now the alternate has similar concerns, saying English is not her first language and is concerned she “could make a mistake in something.” “It’s her future.” The judge does not seem to be having this one.
The juror said she doesn’t believe in punishment and has been increasingly haunted by the thought of having a role in sending someone to jail. Not surprisingly, prosecution was in favor of dismissing her.
I’m starting to feel like an Oompa Loompa watching the jurors drop out from the sidelines here, maybe the press corps will put together a little song and dance.
💉 U.S. v. Holmes, Day 12 of ~2384972: We have dismissed a juror who says her views as a Buddhist will make it impossible for her to vote to convict. Three of five alternates remain. Later today Steven Burd, the former C.E.O. of Safeway, will testify.
QC failure, immulite reagents, clia lab, advia, HCG, PSC, assays, vacutainers, nanotainers, we are nearing the end of Day 5 of Dr. Rosendorff’s testimony and so very deep in the blood testing weeds please send help
Judge Davila now says that defense has had four days to challenge Rosendorff’s testimony and says “You have challenged his confidence.” Allows defense to question about Rosendorff’s work post-Theranos, says to “probe lightly” to avoid liability or impeding his future career.
Interesting style of questioning asking the witness “You don’t recall those times when you lied and again and again?” “…No sir?”
Rosendorff sent himself a bunch of internal Theranos emails before he left. Wade accuses him of stealing trade secrets and violating HIPAA with patient data.
Wade continues to drive at the point that Dr. Rosendorff left Theranos for more money and the reason he expressed concerns about its lab results and asked to be removed from its Clia lab was to start his new job sooner.
Now Wade is trying to use Rosendorff’s resignation email — the fakest email any employee ever writes — against him. “You wrote that it was a ‘tremendous experience’ and you ‘appreciated the opportunity to work with so many talented individuals’” Gotcha!
Wade is trying to make a big deal about how Dr. Rosendorff’s next job after Theranos paid him more. Dr. Rosendorff is not having it. “I wanted to join a reputable company whose mission I believed in.”
Defense shows a résumé Rosendorff was sending around and points out that he said he did great work at Theranos. Rosendorff: “I don’t know if you’ve ever tried to apply for a job but it doesn’t serve you” to discuss “fraudulent activity.” Defense strikes his answer.
Dr. Rosendorff was also looking at other jobs before Theranos ever launched. Defense: “You essentially had a foot out the door the whole time?” “On occasion I would look at what other jobs were available.”
Back from a break. Defense asking Dr. Rosendorff about his departure from Theranos. Defense points out that Rosendorff was considering filing a qui tam lawsuit against Theranos, to alert the government of wrongdoing (and get a percent of the money recovered).
Defense counsel Wade reads from a deposition in which Rosendorff appears to contradict his testimony about the frequency of problems at Theranos labs. “Problems come up in labs — every lab in America, probably every lab in the world — is not going to perfect, correct?” “Yes”
Binder hijinks. While flipping through all the various emails Rosendorff asks someone to help him with the binder because “it’s just opened up and it’s just [hand wave motion] pages everywhere.”
In the meantime Roger Parloff has filed a declaration opposing defense’s push to compel him to turn over his notes in reporting the 2014 Fortune cover story about Holmes and Theranos. He already provided both sides recordings of his on-record interviews with Holmes and Balwani.
Rosendorff takes off his glasses and rubs his eyes as Wade cycles through various forms showing his signoff on assay validation from 2013.
The intended takeaway from the line of questioning, as far as I can tell, is that some tests at Theranos at some point did work and that when there were problems, many people at Theranos tried to fix them.
Lance Wade, defense counsel, has resumed his aggressive questioning of Dr. Rosendorff, getting deeply into the weeds on his role in setting Theranos’s lab policies and QC testing with various emails.
Judge Davila responds with a light dig against defense: “A couple of blue suits sitting next to them in a judge’s chambers, what could be intimidating about that?” 👔
A media coalition (including NYT) has argued to unseal the juror questionnaires since we had little visibility into the final selection process. The judge plans to privately question each juror about what they might want to redact and defense says they want to be there, to which the judge responds that that would be unnecessarily intimidating. Defense disagrees.
Judge Davila said a journalist contacted a doctor who contacted the court clerk to point out that one of the defense’s exhibits included a patient’s real name, which is a HIPAA violation.
Holmes is here of course with Billy Evans, her mom and an older man I can’t ID. Before the jury arrives, the lawyers are arguing about whether they can discuss problems at companies that Dr. Rosendorff worked for after Theranos.
🩸 Back in the courtroom for U.S. v. Holmes. 🩸 The clerk is checking courtroom tickets after a few book clubs showed up last week. Cross-examination of ex-lab director Adam Rosendorff continues.
With that, we’re breaking for the weekend. Court will resume on Tuesday.
The government asks how long Wade is going to take with cross-examination, given that they have out-of-state witnesses they want to call next. Wade says he expects it’ll take all day Tuesday. (As a reminder, the public does not typically get information on what witnesses are coming next.)
7/19/14 email from Rosendorff to Balwani defending Theranos’s tests in response to physician complaints. “I was emphatic with Dr. Chen about our rigorous validation and quality process,” Rosendorff wrote. He testifies that he believed this at the time.
With five minutes left before we’re scheduled to break for the weekend, we are now discussing customer service. Rosendorff notes that by the time complaints were escalated to him, they were usually serious issues.
Wade really hammering home this point on outlier removal (which makes sense — this is something that came up a lot in previous testimony as an example of Theranos manipulating results).
Wade is pressing Rosendorff to say he approved of this. “I thought it was unusual,” Rosendorff said. After reminding Rosendorff of what he said in his deposition, Rosendorff concedes that he approved it.
Now onto something called the “six tip policy,” where there are six results from one sample. Two results can be discarded, and you average the other four. Young developed this process. Rosendorff says there was no formal SOP about outlier detection.
6/4/14 email from Young, saying that they’re holding the results of a study after speaking with Rosendorff — presumably supporting Wade’s line that Rosendorff is now in the loop.
In a 6/4/14 email from Rosendorff, he wrote a HCG plan for Balwani and Young which said HCG should switch to vacutainer draws and run on immulite. Wade notes that Rosendorff is “in the loop now.”
Young replies that he updated Adam over the weekend and agrees that “they should be running all decisions by Adam.”
Looking at 6/3/14 email from Balwani to Young: “Adam came by my office EXTREMELY frustrated that as a lab director he is not being kept in the loop.” “This information has to go through him. … Can you guys please touch base with Adam so he is in the loop,” Balwani adds.
Wade asks if Rosendorff stands by his testimony that he didn’t meet with Holmes about HCG in this time period. Rosendorff says yes.
5/30/14: email from Holmes’s assistant where she writes that “Elizabeth has asked me to coordinate a CLIA meeting for this afternoon at 4 p.m.”
Now seeing Holmes’ calendar for 5/29/14, where she has “meeting with Adam Rosendorff” listed. Rosendorff had testified that he had not met with Holmes.
We’re now building a timeline being shown to the jury about HCG issues, including various emails and exhibits.
Wade had Rosendorff confirm that he testified Holmes was less concerned than he was about the HCG issues. Then, he showed a 4:45 p.m. email forwarded from Balwani to Holmes about HCG issues. Holmes responded six minutes later, asking, “How did that happen?” Wade then moves on.
We’re back from break and switching gears to talk about HCG, the pregnancy test.
On 10/15/14, Balwani offers another meeting, but Rosendorff’s response indicates that he doesn’t need the other meeting.
Wade now discussing how Daniel Young sent a draft Q.C. policy ahead of the meeting, even though that was Rosendorff’s responsibility. Wade also notes that there were no restrictions on what Rosendorff could discuss during the meeting.
Wade is also trying to show that Theranos DID take Rosendorff’s concerns seriously. On 10/9/14, Balwani emailed Rosendorff, setting up a meeting to discuss his concerns. Balwani tried to set it up for the next day, but Rosendorff asked for it to be delayed.
In today’s cross-examination, Wade seems to be trying to poke holes in Rosendorff’s credibility — pointing out times when he was slow to respond to doctors, and noting that there was an AAP in place for proficiency testing, contrary to the impression given in previous testimony.
Wade asks if anything was going on to make Rosendorff slow to respond. Rosendorff: “I was becoming frustrated at my inability to explain discrepant results.” Wade presses him that he just needed to call the doctor back.
We’re now seeing another email from a doctor saying he’s waiting for a callback from Rosendorff. Wade makes the point that this is the second time a week had passed before returning a doctor’s call. Rosendorff says he had already spoken with him and didn’t realize another call was needed.
Email from Rosendorff after talking to the doctor: The doctor is “puzzled” about the results, but “the MD is extremely positive and excited about Theranos and wants us to ‘crush Quest Diagnostics.’”
There’s a 10/10/14 email from a customer service rep to Christian Holmes about a patient who redid her labs at Stanford and got very different results.
Christian responds to say they’ll repeat the tests and loop Rosendorff in. Rosendorff was looped in as instructed, but now there’s a followup email to Rosendorff! A week had gone by, and he hadn’t returned the phone call about the patient.
So far this morning, Wade’s cross has consisted of going through email chains discussing proficiency testing, seemingly to establish that Theranos did have a rigorous proficiency testing protocol in place.
We’re starting off with proficiency testing. Wade gets Rosendorff to agree that he did write a standard operating policy for an alternative assessment protocol for proficiency testing.
Court is in session for the fourth (!!) day of testimony by the former Theranos lab director Adam Rosendorff. (This is the longest any witness has been on the stand thus far.)
There is no redirect, and Sung has been dismissed. Court is on recess until Friday.
The defense ended on the contract between Celgene and Theranos. Cline said that all of the “success milestones” were achieved, and payments were made, although Sung said she didn’t have direct knowledge of the payment.
John Cline is doing the cross-examination for the defense. He’s starting by going back through the chronology we covered in direct.
And now we’re onto cross! This was a very fast direct examination.
Sung did not tell anyone that Celgene had comprehensively validated Theranos’s technology.
4/2/12 email from Sung to Daniel Edlin, with Holmes and Young copied. “We thought it would be great to keep her in the loop and aware of ongoing activities,” Sung said. The email says Celgene “had decided to simply wait until your next-gen machines are ready and then deploy them”
In more bad news for Theranos, mean concentration profiles were not consistent between Theranos and QPS, and concentration variability was higher with Theranos than with QPS method. Once again, Sung confirms that concentration variability is undesirable.
We’re looking at a scatter plot showing the range where Theranos tests should fall. Most of them … do not fall within this range. 67% of samples had >25% difference in serum concentration between Theranos and QPS method. “It’s not good news” for Theranos, Sung said.
Theranos whole blood data showed more fluctuations, which Sung said was undesirable.
Theranos also had higher variability. Government asked if that was good or bad. Sung chuckled and replied: “Bad.”
14.1% of Theranos samples didn’t have usable results, compared to less than 2% for QPS.
We can see a comparison between Theranos and QPS assays. Theranos only used .25mL of blood compared to 2mL for QPS. Theranos also used whole blood rather than serum, which Sung said was “very nice.”
7/20/10 email from Sung to Holmes saying they weren’t able to validate Theranos’s tests. The results were “close” in some cases but not good enough.
She had visited Theranos and thinks she met Holmes while she was there. She saw a Theranos device while she was there and said it looked like an oven. The idea you could do something so small and efficient on site was a “great idea,” she thought at the time.
Celgene entered into an arrangement with Theranos. Her understanding was that Theranos was developing a platform to analyze the endpoints. She thought they could do it efficiently with a very small amount of blood, which would be a “huge advantage.”
We’re starting her testimony in 2009, when she worked on a drug called ACE-011 being developed for treatment of anemia and bone loss. Her role was to suggest proteins in the blood to measure that would suggest whether the drug was working (e.g., hormones).
Dr. Sung got a Ph.D at Georgetown and then did a postdoc at Stanford before going into industry. She worked in various biotech firms, including Celgene, which was later bought by Bristol Myers Squibb. She’ll be testifying about her work at Celgene.
We’re back in session. The government is calling Dr. Victoria Sung. (Rosendorff will pick up on Friday.)
After a long discussion of an email chain about proficiency testing, Rosendorff is done with testimony for today. (He has a conflict this afternoon.) We are going to take a 20 minute break and then pick up with a different witness for the rest of the afternoon.
Now looking at a document from the American Proficiency Institute that gives “Acceptable” scores to all of the proficiency tests.
Looking now at an email from Rosendorff: “We are continually doing proficiency testing.” Rosendorff testifies to clarify that this was predicate testing.
After looking at his 2016 testimony (in the binders!), Rosendorff says he still doesn’t remember telling the government that. “I assume the record is correct,” he says.
We’re now back to where we started yesterday, discussing Rosendorff’s contact with the government. Wade asks Rosendorff if he remembers telling the government that Theranos machines used alternative assessment proficiency to measure accuracy. Rosendorff says no.
Rosendorff previously testified there was no formal proficiency testing processes in place. After Wade challenges him, Rosendorff clarifies: There was proficiency testing for predicate testing (commercial tests), but not for Theranos tests
Looking at a quality systems presentation for 2014 from Langly Gee, Theranos’s quality control manager. Wade is showing failure rates for Edison quality control tests. “Something’s not squaring up,” Rosendorff says — these failure rates are lower than he thought they were.
Wade is continuing on this line of questioning, noting that Rosendorff testified about concerns in June 2014 but signed validation reports in Aug. and Sept. 2014.
Rosendorff testifies that he would not have continued signing validation reports for Theranos’s blood testing device, the Edison, if he thought it was unreliable.
We’re back from break! And on to another Edison validation report.
We’re going through a Sept. 2013 validation report on the Edison for TSH, a thyroid test. This document, with Rosendorff’s signature, validates the test for patient use. Wade is walking Rosendorff page by page through the report.
Rosendorff testifies that he never told the CLIA team to stop using the Edison test altogether, but did on some specific tests.
Wade is now noting that Rosendorff was among the highest-paid employees at Theranos. Rosendorff says that he thought he should have been paid more, given Theranos’s problems, but this is stricken from the record.
Rosendorff says he had concerns about QC. Wade says he was paid to have concerns. “That’s why you get paid the big bucks.” Rosendorff replies: “Not as big bucks as you get paid.” Cue the biggest laugh of the trial so far.
Wade is making a point he’s made before, that quality control samples aren’t patient samples — noting that “nothing bad happens” to patients if a QC test fails.
We are now on to a mid-Jan 2014 email from Rosendorff to the CLIA lab team asking them to refer to very detailed quality-control policies.
Balwani’s response: “I spoke with the teams today and they are all going to put in long hours and do whatever it takes to get this done tomorrow.” Rosendorff testifies: “I had many many battles with Sunny about what was needed versus what he was prepared to allow.”
Rosendorff added: “I do feel that it was very difficult to get answers from Daniel’s team.” In a later email, Rosendorff doubles down on needing the specificity studies: “No they are required. Very important in fact.”
From the email chain. Balwani: “As we know, we take these issues with seriousness. Why didn’t you raise these before to me when I was asking for any issues for months?” Rosendorff: “My apologies for the late feedback regarding our readiness …”
Notable frustration from Rosendorff after he tries to make a point and Wade cuts him off: “I’m just reading emails and saying, yes, that’s what’s happening here.”
We’re now onto discussion of the Walgreens launch. In a 11/10/13 email to Balwani, Rosendorff flagged issues that needed to be addressed before the Walgreens launch. Wade is walking him through the email chain with Balwani, point by point.
After many questions establishing that Rosendorff did not hide Normandy lab from the inspectors, Wade notes that the inspection found “minor deficiencies.” Rosendorff says that Holmes and Balwani were upset that there were deficiencies and that a clean report would have been “ideal.”
Wade is trying to make the point that this was to preserve trade secrets. Rosendorff says this doesn’t make sense, asking who would pin trade secrets to a bulletin board.
We’re looking again at the email from Elizabeth Holmes about walking the auditors through the lab. We’re now seeing the response: “All of the bulletin boards from the lobby to HR were covered with paper so the inspector could not view any of the drawings or items on the boards.”
Wade is starting by asking questions about the Dec. 2013 CA Dept. of Public Health audit that we discussed yesterday. Wade’s going through a document listing preparations for the audit as he tries to establish that Rosendorff had responsibility here.
Court is in session for another day of the Elizabeth Holmes trial! We’re continuing with the cross-examination of former Theranos lab director Adam Rosendorff, which defense attorney Lance Wade expects to take all day.
Rosendorff asked for a bathroom break, and we are instead ending for the day! Will pick back up at 9 a.m. Pacific Time tomorrow.
Important content: The custom-built laboratory information system was named Super Mario. (Other fun names: Jurassic Park = the lab with all of the standard machines, Normandy = the lab with Theranos machines.)
Cross examination has been much slower and calmer now that we’re back from break. Less pressing Rosendorff to answer specific questions and more jokes.
Wade is holding up a copy of the book and talking about the importance of its PR and marketing efforts, as well as its secrecy.
Rosendorff read Walter Isaacson’s Steve Jobs biography and liked the excitement of Silicon Valley, which helped lead him to Theranos. (That Steve Jobs biography was a favorite of Holmes’s, too.)
We’re back from break! And we’ve taken a big step back in time — now looking at the resume Rosendorff sent Theranos when he applied in 2013.
We’re now going back and forth on who was involved in the R&D process. Rosendorff says he was not aware at the time if Holmes was involved with R&D. Per the master validation plan, Rosendorff had to sign off on each assay before it can go into validation.
We’re going through what tests were offered during the friends and family launch. The only tests run through 9/28/13 were two that did not run on the Edison, Rosendorff confirms. The first Edison-based test, TSH, a measure of thyroid function, was run 10/17/2013.
Wade also keeps having Rosendorff read his own testimony, silently, to himself. That’s happening again now.
In the email, Balwani writes, “We feel confident we can handle ~30 samples/day from this location at this point. And it has been 2 months since we have been out in WAG [Walgreens]. It’s time to go live.” Wade now trying to make the point that they had not previously been live.
Found it! We are now looking at an 11/7/13 email from Balwani to Rosendorff about opening their Palo Alto/Uni Ave location to the public on the coming Monday. It had previously only been open to friends/family.
We are now, once again, trying to find the correct pages in the MANY binders the defense gave Rosendorff.
Wade is now saying that Rosendorff testified earlier to a grand testimony that it was a “limited friends and family” but didn’t do so on Friday.
We are now on to the commercial launch. In an email that we saw in direct, Rose Edmonds (a development scientist) says that none of the assays are completely thru validation testing. Rosendorff had testified this is significant because they were just a week from launch.
Wade gave a hypothetical where Rosendorff had rotten food in his office, and subordinates complain to Balwani. Rosendorff continued to seem confused, and Wade is now moving on.
We are now … asking about company hierarchy? (Rosendorff reported directly to Balwani, and Young was also above him.) “Are there ever circumstances where it’s appropriate for senior management to have discussions about a subordinate?” Wade asks. Rosendorff seems confused.
Rosendorff also served as Theranos’s clinical consultant. Holmes wouldn’t qualify for this either.
Wade is asking about Holmes’s education. Famously, she dropped out of Stanford. “Based on your understanding of her background, would she be qualified to be a CLIA supervisor or lab director? Rosendorff: “No, definitely not.”
Wade says, and Rosendorff concedes, that ultimately it was Rosendorff’s responsibility if the tests failed and his responsibility to enforce quality control policies and proficiency tests.
Rosendorff is agreeing with Wade’s questioning that Holmes never told him to report an inaccurate result, and that Holmes never directed him not to pause or discontinue tests he thought were inaccurate.
Wade: “Did you ever use a test on patients that you believed was inaccurate or unreliable?” Rosendorff: “No.” Did he ever provide results that he believed to be unreliable? “No.”
Wade: “Did you faithfully dispatch your legal obligations as lab director at Theranos?” Rosendorff: “Yes, I did.” Wade: “Did you offer lab tests that you knew at the time were inaccurate or unreliable?” Rosendorff: “No … I ordered the laboratory to cease testing.”
Two themes of cross thus far: Wade seems to be trying to prove that Rosendorff worked with the government in shaping his testimony, and is hammering home that Rosendorff was legally and ethically responsible for the lab.
Rosendorff confirms that he was familiar with the regulations. Wade is now asking a series of questions about Rosendorff’s obligations: “You are required to…?” Rosendorff says these are his obligations, but “I received pushback from management.”
Wade is now holding up a stack of papers (maybe an inch thick?) and asking if Rosendorff knew all of those regulations, presumably the stack of papers he’s holding. Davila, the judge: “You’re asking to admit the entirety of this document? It’s how many pages? 122?” It’s admitted.
We’re into Rosendorff’s time at Theranos! Wade asked him if being the CLIA lab director meant he was legally responsible for what happened in the lab, and Rosendorff said yes.
Wade is continuing to try to pick apart the prosecution’s case, noting that they didn’t go in chronological order through the documents. He still hasn’t really asked about Rosendorff’s actual experiences at Theranos.
Wade is arguing that Rosendorff’s testimony in direct doesn’t match what he testified in 2019. Earlier, he just said he wasn’t satisfied with management’s response to proficiency testing. His testimony on Friday was more detailed.
We’re now into questioning about the testimony itself. Wade is asking Rosendorff about his reasons for leaving Theranos. Wade asks if Rosendorff discussed that question/answer with the government. Rosendorff says yes.
Wade presses him on whether he told the government what he was going to testify.
Rosendorff says no.
Wade is now asking about how Rosendorff was prepared to testify by the government. Rosendorff: “I was always instructed by the government to be truthful.” Wade asked: “Did they tell you to give that answer?” Rosendorff: “No.”
Wade is going through a list of people and asking Rosendorff if he’s met each of them. His tone is far more aggressive than with previous witnesses.
We’re starting with cross-examination. Lance Wade, Holmes’s lawyer, is starting by grilling Rosendorff on how many times he’s met with the government.
And, with that, his direct testimony has wrapped. We’ll pick up with cross-examination after a 30-min. break.
Ultimately, Rosendorff said, he left after “endless meetings and conversations, very careful study of medical literature, late nights … great efforts on my part to improve the quality of testing at Theranos.”
Rosendorff testified about why he spoke with then-WSJ reporter John Carreyrou: said he felt a “moral and ethical” obligation to alert the public.
Bostic pointed out the line “We will execute this year.” When did Theranos start testing? he asked. Rosendorff responds: 2013.
More texts from Holmes/Balwani! Holmes: “This year is our year. We can never forget this tiger.” Balwani: “I know, I am focused on it. We will execute this year.” Holmes: “I know. I’m focused on it too. And for our kids never forget who we are.”
On Rosendorff’s last day, he says Balwani offered a handshake, and he declined. Balwani gave him exit paperwork to sign. Balwani said he would be prepared to keep him on, but Rosendorff said it wasn’t worth the risk to his reputation.
Holmes forwarded it to Balwani: “We need to respond to him now and cut him Monday.” Rosendorff had already accepted a job offer at another lab and was planning on leaving — interpreted this as them trying to fire him right before he left.
Nov. 2014 email to Rosendorff asking for a redraw. Rosendorff forwarded this to Holmes/Balwani, and Balwani said the rep “jumped the gun” asking for a redraw. Adam forwarded this to Elizabeth: “I find Sunny’s response offensive and disingenuous. He should apologize.”
Gov’t trying to make the point that Holmes/Balwani are actively courting investments even as Rosendorff raises concerns about crucial problems in the lab.
We’re now looking at Nov. 2014 texts between Balwani and Holmes, talking about investments from Alice Walton and Rupert Murdoch. Balwani: “They are not investing in our company, they are investing in our destiny.”
“…how fundamental it is to all of us for you or any other employee never to do anything you’re not completely confident in.” Rosendorff says he disagrees with this, and we’ve seen emails showing that he raised concerns.
Holmes’s response (pt. 1): “How sad and disappointing to see this from you. Outside of the fact you’ve never emailed me on any concerns you allude to there before but now email this, you know from every conversation we’ve ever had together …”
Now looking at Nov. 14 emails from Rosendorff. “I feel really uncomfortable with what is happening right now in this company. Is there any way you can get Spencer back on the CLIA [Clinical Laboratory Improvement Amendments] license and take me off? I am feeling pressured to vouch for results that I cannot be confident in.”
Christian forwarded the email to Elizabeth, writing: “His response to this was to do a vacutainer redraw & I ended the conversation at that point.” A vacutainer draw is a non-Theranos retest.
He continued: “Further 100% honesty and transparency to the patient is essential. “My first duty is not to Theranos, but to the patient as per my Hippocratic oath “primum non nocere.” “I never said I wouldn’t talk to the MD.”
In an email to Christian, Rosendorff doubled down. “This is not a question of interpreting results — this is a question of the reliability and accuracy of the result.” “The most constructive thing at this point is to offer reliable and robust assays, not to spin.”
Nov. email from Rosendorff about the patient call to Christian: “If you’re asking me to defend these values then the answer is no.” He was refusing to defend the accuracy of the result, Rosendorff testifies.
Emails like this contributed to a “crescendo” of issues, Rosendorff testifies, leading to his resignation in Nov. 2014.
Looking at an email from a medical assistant concerned that HDL and LDL (cholesterol) readings are not adding up. That raises concerns about the accuracy of the test, Rosendorff testifies.
In a follow-up email from Holmes: “Kerry please delineate this based on what we did with the NY inspector recently and send that out.” No one was allowed to enter or exit the Normandy lab during the visit, Rosendorff said. Those directions came from Balwani.
1/26/13 email from Holmes about the upcoming audit from the California Dept. of Public Health: “Let me know if the path for walking the auditors in and downstairs has been cemented so we avoid areas that cannot be accessed, and what that path is.”
Christian forwarded the message to Daniel Young and cc’d Elizabeth. In a later email to Elizabeth and Daniel, Christian wrote that Rosendorff already approved the redraw. “Need to discuss messaging for my call with this doc, with regard to reason for the redraw,” Christian wrote.
Now looking at an email to Christian Holmes to approve a redraw, despite his not having a position in the clinical lab or a medical/science background. Rosendorff says he wasn’t aware Christian was involved in approving redraws.
Now onto discussing transparency. “I felt a conflict between the messaging that the company wanted me to provide … and my duty as a physician” to accurately report results when talking with doctors, Rosendorff says.
In an email chain about the proficiency testing samples, Balwani wrote that Theranos’s validation has been “excellent in the past” and that “it is these PT samples that are off.” Rosendorff testifies that he disagrees.
There was no formal proficiency testing process at Theranos, Rosendorff says. He says he raised these concerns at a mid-2014 meeting to people including Holmes, Theranos’s president, Ramesh Balwani, and the VP Daniel Young. He felt like they gave “lip service” to this issue, and there was no progress made before he left in November.
Rosendorff’s reaction to situations like this: “Every time we got a physician complaint, every time our QC would fail, every time we had a spate of anomalous results, it raised great concerns to me about the accuracy of the testing process.”
We’re looking at an email from someone who has been on coumadin, a blood thinner medication, for 13 years. After switching to Theranos testing, her results came back low, and she increased her dose as a result. “I have not felt ‘right’ since the one increased dose,” she wrote.
I’m back in the courtroom for another day of the Elizabeth Holmes trial! We’re starting with the end of former lab director Adam Rosendorff’s direct testimony.
With that, we’re going to break for the weekend. I’ll be in the courthouse Tuesday, Wednesday and Friday next week — see you on Tuesday!
For the past hour, Rosendorff has testified about problems w various tests, incl. the potassium, chloride and sodium tests. In a 10/27/14 email, he wrote: “I am not sure of the clinical value of a sodium assay, in which the only time we can report it is when it is not critical”
We’re now getting into Rosendorff’s decision to leave. He forwarded work emails with issues of concern to his Gmail account in 2014, testifying that “I wanted to protect myself.” He also says he started looking for another job in mid-2013, shortly after joining Theranos.
Today’s theme seems to be a) Rosendorff was concerned about faulty tests, b) Rosendorff recommended the company stop using those tests and c) Holmes/Balwani were aware but declined to change course.
We’re now on issues with Theranos’s HDL (cholesterol) tests. Rosendorff says he “suspected” Theranos’ HDL was no longer working as of Feb. 2014 and suggested reverting to FDA-approved devices, but received pushback from Balwani, Holmes and Theranos VP Daniel Young.
We’ve now seen two email chains including Holmes/Balwani about complaints/issues that Rosendorff wasn’t included on. Rosendorff says he “absolutely” should have been included on the emails.
Rosendorff is testifying about issues with the hCG tests, which detect pregnancy. In June 2014, Christian Holmes wrote to Elizabeth: “Just fyi-hCG right now causing some serious issues and patient complaints.”
We’re comparing Rosendorff’s time at the University of Pittsburgh to his time at Theranos. At Theranos, complaints about test results were “much more frequent,” and he “felt pressured to defend the company’s results to physicians,” he said.
Theranos devices failed so frequently that it raised questions about the accuracy of the results, Rosendorff testifies. Performance of Theranos assays was worse than non-Theranos analyzers.
Rosendorff is now discussing quality control. As we learned in Cheung’s testimony, quality control happened once a day, and machines would be recalibrated if they failed. This was a frequent discussion topic at Theranos, he testifies.
Rosendorff had a meeting w Holmes where he expressed his concerns. She was very nervous and was not her usual composed self, he said: She was trembling, knee was shaking, she was very upset.
In an email to Holmes, Rosendorff wrote that “A few more weeks to sort through these medical and logistical issues, and getting the proper level of training and staffing would help us tremendously.”nd staffing would help us tremendously.”
An email from Rose Edmonds from 9 days before the launch says “none of our assays are completely through validation including clinical sample testing with fingerstick.” Under CLIA law, the tests need to be validated properly before they can be used for patient care.
Leading up to Sept 2013 commercial launch, there was “a lot of anxiety” about the appropriateness of using modified tests for patient care. The general mood of the company was “very optimistic,” but some were questioning why Theranos wasn’t using its own devices.
The downstairs Theranos lab, which contained the Theranos Edison devices, was called Normandy, Rosendorff said. According to Rosendorff, Balwani called the upstairs lab with conventional devices Jurassic Park: Balwani “believed the conventional devices were dinosaurs.”
Rosendorff starting strong with why he quit Theranos, incl. unwillingness of management to perform proficiency testing and feeling pressured to vouch for tests he wasn’t confident in. Also: “The company was more about PR and fundraising than patient care.”
The government is calling former Theranos lab director Adam Rosendorff today in the trial of Elizabeth Holmes. Per prosecutor John Bostic, this testimony is likely to take all day.
Mattis is done and now a prosecutor is reading text messages between Holmes and Balwani while a forensics guy from PWC says “yes” and “correct.” I guess this is how they have to present this evidence but it is really really bizarre.
On redirect: Why did Mattis initially support Holmes after the WSJ expose and then change his mind? There were too many surprises, he said. “We were unable to help her on the fundamental issues that she was grappling with if we only saw them in the rearview mirror.”
We look at Mattis’ emailed response to Holmes after the WSJ article. “Be swift in response with unassailable truth,” he wrote. “I have full faith in our plan.”
He also asks if Mattis knew Theranos was doing blood tests in a central lab.
Mattis: “I assumed the central Theranos lab was the Theranos machine.”
In cross-exam, Holmes lawyer Kevin Downey asked Gen. Mattis about his qualifications to evaluate Theranos’s technology and be a board director.
Initially Mattis thought the problem was fixable — the company simply messed up its messaging and could come clean. Soon after, he began to question whether or not the Edison machine worked. “There just came a point when I didn’t know what to believe about Theranos anymore.”
After WSJ article, board members emailed Holmes about the allegations. Her response: Theranos was transitioning from operating under one laboratory framework to another. Mattis: “I was still confused.” At a minimum, “we had a reputation problem here and an integrity problem.”
Ominous. After Theranos learned about a 2015 WSJ article by John Carreyrou that exposed problems with Theranos’s technology, there was a board meeting with a slide titled “Duty of Loyalty.” We are shown that slide, except it is comically redacted — all content blacked out — and Mattis doesn’t remember it.
We see an email from Holmes instructing Mattis that, in an interview with Ken Auletta of The New Yorker, he can’t discuss “how our technology works (i.e. that there is a single device that does all tests)”
Fortune published a long correction to that article, which I don’t remember seeing from a lot of other outlets that wrote positive stories. Parloff is listed as a witness and defense is attempting to compel him to turn over his notes.
Assistant U.S. attorney John Bostic pulls up Fortune’s 2014 cover story about Theranos. Mattis spoke to the reporter, Roger Parloff, and said Holmes gave him guidance on what he could and couldn’t say.
Still trying to train my brain to not hear “amino acid” every time they say “immunoassay”
Theranos got a lot of mileage out of a 2013 WSJ article! We see an email where Holmes sends Mattis the link, as well as a slide of it in a Theranos board presentation
We’re going through this board presentation, which has a slide claiming Theranos’s tech had been validated by 10 of the 15 largest pharmaceutical companies, alongside logos of FDA & WHO and a quote from Johns Hopkins.
What were your sources for information about the company? Mattis: “Ms. Holmes.” “Was she the primary source?” “The sole source.”
Mattis also invested $85k into Theranos, which he said was a significant sum “for someone who had been in govt. service for 40 years.”
Did you accept Ms. Holmes’s invitation to join Theranos’s board? “Yes I did, after asking why. I was not a medical person.” She said she wanted his mgmt. and organizational experience.
Mattis testified that he was not aware of Theranos devices ever being used on battlefields, military helicopters, clandestine operations…
Mattis testified that Holmes was “very aggressive” at wanting the military pilot program to get going. “She was very confident that if we got it in there, it would prove itself.” He knew it was a start-up, but noted that Holmes had been working on it for a decade by 2013.
oy, another email where Mattis calls Holmes “young Elizabeth.”
Holmes was the one telling him about the Theranos device’s capabilities, he said. “I was frankly amazed at what was possible.” But he added: “That didn’t take the place of having the device prove itself.”
Mattis testified the size of the Theranos device and its promised capabilities made it so attractive to potential military use. Accuracy and reliability were critical given the casualties, he said. “The stakes are very high.”
In one email, Mattis told Holmes he wants to explore a pilot project to test Theranos machines alongside the army’s existing systems to compare. Mattis testified that he was very “taken” by the possibilities of using a drop of blood for diagnostics.
Mattis, a U.S. general and former secretary of defense, was on Theranos’s board between 2013 and 2016.
We start by looking at 2011 emails between them after meeting. In one, Mattis writes, “thank you for your note, young Elizabeth, and I wish you every success.”
At the courthouse for US v. Holmes. James Mattis has taken the stand.
Gould’s testimony lasted around 15 minutes – From behind a clear mask, she got emotional discussing her experience finding out via Theranos tests that, after three miscarriages, her fourth pregnancy was not viable. The happy ending is that it was. She had a baby. Adjourned!
Defense wraps up by pointing out that Zachman’s practice had many many test results from Theranos beyond Ms. Gould that seemed to be fine. Judge Davila is eager to keep going, even though we are over on time today. Brittany Gould takes the stand.
Defense works to chip away at the testimony by implying that the Theranos test results simply existed on a different scale and should have been “rebaselined.” Also noted that Holmes’s brother Christian, who responded to Zachman’s complaint about the results, apologized.
Oh my, Theranos offered Zachman a “corrected” version of the results which simply removed a decimal point but the she says numbers still wouldn’t have made sense within the context of a viable pregnancy or a loss of one.
“This circumstance was very impactful to me as it stood out as such a red flag for the pregnancy.”
Gould took 5 blood tests, 3 from a subsidiary of Quest Diagnostics and 2 from Theranos. She went on a rollercoaster, with the Quest test showing she was pregnant, the two Theranos tests showing a miscarriage, and 2 more Quest tests showing she was indeed still pregnant.
Zachman describes the case of a patient named Brittany Gould (sp?) who had had 3 miscarriages. She came to see Gould after a positive at-home pregnancy test “to establish that yes, she is pregnant and look at the health of the pregnancy.”
Zachman was on a committee that evaluated service providers and her practice adopted Theranos blood tests around 2014. Theranos even set up a lab downstairs from one of her practice’s offices, which Zachman said was “very exciting.”
New witness: Audra Zachman, a nurse practitioner at an OB-GYN practice.
I have enjoyed chatting with some of the trial-heads and and fans of justice who have shown up to watch (provided they’re not moles :). Today I met a retired paralegal who says he was at the Patty Hearst trial!!
Redirect up. US Attorney Robert Leach reminds jurors that when Gangakhedkar resigned from Theranos, she had concerns about the reliability of Theranos’s tests and discussed them with Holmes.
More bad boss/good boss content: We see an email Gangakhedkar sent to Balwani defending how hard her team was working + an email she sent to her team praising their long hours. She then resigned from Theranos and Holmes attempted to get her to stay, offering time off.
Defense previously showed that Holmes let Gangakhedkar go to India to see family, painting her as a sympathetic boss and Balwani as the aggressive one. “[Balwani’s] trying to make you feel guilty that you weren’t working?” “Yes” “You were frustrated by that?” “Yes.”
We are still doing cross-examination of Gangakhedkar.
Wade shows an email from the former Theranos president, Ramesh Balwani (who goes by Sunny), chastising the lab workers for not working as hard as his software team, painting him as the one pushing unrealistically for overwork.
Zachman will now offer expert testimony on interpreting HCG tests (a hormone used to identify pregnancy status)
You expect HCG levels to double every 48 hours or so in early pregnancy.
Wade goes on a run of questions (peppered with “yes” responses by Gangakhedkar) arguing that the point of R&D is encountering issues and setbacks and fixing them.
“In R&D sometimes you have to fail before you can succeed right?”
We see an email where Holmes asked Gangakhedkar for some testing data ahead of a meeting with the DoD. Gangakhedkar emails that Vitamin D data isn’t ready and Holmes writes asking for data on other tests. The point is, apparently, look at this example of Holmes not doing fraud.
The Defense strategy re: Theranos lab problems seems to be: look, real work was being done; there were processes in place that sure seemed rigorous; the very people pointing out problems also signed off on it all.
So far it’s basically a call and response, where Wade describes work of Gangakhedkar + Theranos’s lab, and Gangakhedkar replies “yes.” “Were you proud of that work?” “Yes.” “And others at the company were happy about that work as well?” “I think so.”
Back in the San Jose courtroom today for more US v Holmes. Surekha Gangakhedkar, a scientist at Theranos, is back on the stand being cross-examined by Holmes’s lawyer Lance Wade.
With that, Judge Davila is ending Gangakhedkar’s testimony for the day and instructing jurors not to consume media content about the trial, as always. The trial will resume on Tuesday — Erin Griffith will be at the courthouse to bring you live updates.
We are now onto cross-examination. Holmes’s lawyer is questioning her about G.S.K.’s study of Theranos’s assays, pointing out that the study promoted her work. “The Theranos system eliminates the need for a lab and provided quality data,” the G.S.K. memo said.
Despite having signed an N.D.A., Gangakhedkar printed out some documents and took them home when she left Theranos. “I was worried that I would be blamed,” she testified.
Three days after the email from Balwani, Gangakhedkar sent Holmes her resignation email. She testified that she was “very stressed and unhappy and concerned” with the planning of the Walgreens launch.
In an email from Balwani to Gangakhedkar, with Holmes copied, Balwani said the software team had been working until 3:07 a.m., but that the Edison blood-testing devices Gangakhedkar’s team worked on were “all sitting idle.” This was an example of the pressure they were under, Gangakhedkar said.
And, with that, Cheung has been dismissed. The government is calling Surekha Gangakhedkar now, a former Theranos team manager.
The government is now asking questions about a document that says, among other things, that Theranos’s devices “can be operated with minimal training” and that its results have “precision and accuracy equivalent to traditional clinical laboratory analyzers.” Neither is true, Cheung says.
Cheung said they were constantly having to recalibrate the machines, which made results take 2-3 days rather than the couple hours promised. “We had people sleeping in the car because it was taking too long,” she said.
Cheung just said she “became concerned about a month in” with the vitamin D samples, in November of 2013. She was concerned about the performance of the tests and that they were being used on patient samples.
Defense is done with cross-examination, after showing Cheung Theranos policy documents she said she’d never seen. The government is now asking questions again for redirect.
Holmes’s lawyer is asking Cheung a lot of questions about quality control checks that occurred on the Theranos devices. “There is a recognition that some errors would happen and this was the policy on how to deal with those errors,” he said.
Erika Cheung is now taking the stand as cross-examination continues.
The update you’ve all been waiting for: The judge is STILL pronouncing it ther-AH-nos.
In the courthouse now for another day of the Elizabeth Holmes trial. We’re expecting to wrap up testimony today from Erika Cheung, one of the key whistleblowers in the case.
That’s it for today.🩸💉⚖️
So far the theme of the cross-exam of Cheung seems to be using excruciatingly arcane details about the processes and procedures of the Theranos lab to show that its work was very complicated, involving lots of smart, pedigreed people.
Cheung testified that in meetings about quality control failures, Theranos’s lab directors ignored the most obvious possible reason for the failures: “The Edison devices didn’t work.”
Trial gear alert: A reporter brought their own binoculars to see the exhibits on the TV screens.
Erika Cheung is back on the stand.
She described Theranos’s practice of demoing blood tests for V.I.P.s, where some of the results came from Theranos machines and others from Siemens analyzers.
At this point we have heard lawyers and witnesses pronounce “Theranos” hundreds of times, making me start to wonder whether judge is trying to mess with us by sticking to his “ther-AHHHHH-nos” pronunciation.
I should note the woman who clapped and yelled “you’re a good mom!” at Holmes yesterday suddenly stormed out of the courtroom after Judge Davila warned everyone that yelling stuff like that in front of any jurors could cause a mistrial. I don’t see her here today!
Elizabeth Holmes’s entourage is down to just her mom today.